AstraZeneca (AZN) 6-K 25 Jul 24 2024 Q2 Current report (foreign) Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2024
Document and Entity Information
Entity Registrant Name	ASTRAZENECA PLC
Entity Central Index Key	0000901832
Document Type	6-K
Document Period End Date	Jun. 30, 2024
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024

Condensed consolidated statemen

Condensed consolidated statement of comprehensive income - USD ($) shares in Millions, $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2024	[1]	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Condensed consolidated statement of comprehensive income
Total Revenue	$ 12,938		$ 11,416	$ 25,617	$ 22,295
Product Sales	12,452		10,882	24,629	21,448
Alliance revenue	482		341	939	627
Collaboration Revenue	4		193	49	220
Cost of sales	(2,183)		(1,960)	(4,401)	(3,865)
Gross profit	10,755		9,456	21,216	18,430
Distribution expense	(132)		(131)	(267)	(265)
Research and development expense	(3,008)		(2,667)	(5,791)	(5,278)
Selling, general and administrative expense	(4,929)		(4,986)	(9,424)	(9,045)
Other operating income and expense	60		784	127	1,163
Operating profit	2,746		2,456	5,861	5,005
Finance income	100		64	211	141
Finance expense	(443)		(431)	(856)	(795)
Share of after tax losses in associates and joint ventures	(6)		(1)	(19)	(1)
Profit before tax	2,397		2,088	5,197	4,350
Taxation	(469)		(268)	(1,089)	(726)
Profit for the period	1,928		1,820	4,108	3,624
Other comprehensive income
Remeasurement of the defined benefit pension liability	(43)		17	101	7
Net gains/(losses) on equity investments measured at fair value through other comprehensive income	54		(94)	89	(48)
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss	12		2	12	4
Tax on items that will not be reclassified to profit or loss	12		(29)	(27)	(5)
Total other comprehensive income that will not be reclassified to profit or loss, net of tax	35		(104)	175	(42)
Foreign exchange arising on consolidation	(39)		(209)	(554)	105
Foreign exchange arising on designated liabilities in net investment hedges	2		(94)	(96)	(101)
Fair value movements on cash flow hedges	(52)		33	(138)	89
Fair value movements on cash flow hedges transferred to profit and loss	32		4	102	(71)
Fair value movements on derivatives designated in net investment hedges	23		24	45	40
Gains/(costs) of hedging	(1)		(1)	14	(1)
Tax on items that may be reclassified subsequently to profit or loss	3			38	12
Total other comprehensive income that may be reclassified subsequently to profit or loss, net of tax	(32)		(243)	(589)	73
Other comprehensive (expense)/income, net of tax	3		(347)	(414)	31
Total comprehensive income for the period	1,931		1,473	3,694	3,655
Profit attributable to:
Owners of the Parent	1,927		1,818	4,106	3,621
Non-controlling interests	1		2	2	3
Profit for the period	1,928		1,820	4,108	3,624
Total comprehensive income attributable to:
Owners of the Parent	1,930		1,471	3,692	3,652
Non-controlling interests	1		2	2	3
Total comprehensive income for the period	$ 1,931		$ 1,473	$ 3,694	$ 3,655
Basic earnings per $0.25 Ordinary Share	$ 1.24		$ 1.17	$ 2.65	$ 2.34
Diluted earnings per $0.25 Ordinary Share	$ 1.24		$ 1.17	$ 2.63	$ 2.32
Weighted average number of Ordinary Shares in issue (millions)	1,550		1,550	1,549	1,549
Diluted weighted average number of Ordinary Shares in issue (millions)	1,560		1,560	1,560	1,560
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP.

Condensed consolidated statem_2

Condensed consolidated statement of comprehensive income (Parenthetical) - $ / shares	Jun. 30, 2024	Jun. 30, 2023
Condensed consolidated statement of comprehensive income
Par value per ordinary share	$ 0.25	$ 0.25

Condensed consolidated statem_3

Condensed consolidated statement of financial position - USD ($) $ in Millions	Jun. 30, 2024	[1]	Dec. 31, 2023	Jun. 30, 2023
Non-current assets
Property, plant and equipment	$ 9,630		$ 9,402	$ 8,675
Right-of-use assets	1,203		1,100	949
Goodwill	21,060		20,048	19,960
Intangible assets	39,426		38,089	38,326
Investments in associates and joint ventures	264		147	72
Other investments	1,607		1,530	1,071
Derivative financial instruments	217		228	163
Other receivables	806		803	752
Deferred tax assets	4,734		4,718	3,736
Total non-current assets	78,947		76,065	73,704
Current assets
Inventories	5,667		5,424	5,051
Trade and other receivables	11,047		12,126	11,092
Other investments	160		122	148
Derivative financial instruments	28		116	44
Income tax receivable	1,575		1,426	840
Cash and cash equivalents	6,916		5,840	5,664
Total current assets	25,393		25,054	22,839
Total assets	104,340		101,119	96,543
Current liabilities
Interest-bearing loans and borrowings	(5,067)		(5,129)	(4,556)
Lease liabilities	(292)		(271)	(231)
Trade and other payables	(20,463)		(22,374)	(19,738)
Derivative financial instruments	(51)		(156)	(83)
Provisions	(1,168)		(1,028)	(567)
Income tax payable	(1,525)		(1,584)	(1,200)
Total current liabilities	(28,566)		(30,542)	(26,375)
Non-current liabilities
Interest-bearing loans and borrowings	(27,225)		(22,365)	(24,329)
Lease liabilities	(949)		(857)	(722)
Derivative financial instruments	(61)		(38)	(68)
Deferred tax liabilities	(3,333)		(2,844)	(2,800)
Retirement benefit obligations	(1,326)		(1,520)	(1,078)
Provisions	(1,074)		(1,127)	(1,357)
Other payables	(2,208)		(2,660)	(2,398)
Total non-current liabilities	(36,176)		(31,411)	(32,752)
Total liabilities	(64,742)		(61,953)	(59,127)
Net assets	39,598		39,166	37,416
Equity
Share capital	388		388	387
Share premium account	35,199		35,188	35,163
Other reserves	2,078		2,065	2,076
Retained earnings	1,847		1,502	(234)
Total equity attributable to owners of parent	39,512		39,143	37,392
Non-controlling interests	86		23	24
Total equity	$ 39,598		$ 39,166	$ 37,416
[1] The Condensed consolidated statement of financial position as at 30 June 2024 and 30 June 2023 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2023 has been audited by PricewaterhouseCoopers LLP.

Condensed consolidated statem_4

Condensed consolidated statement of changes in equity - USD ($) $ in Millions	Share Capital	Share Premium account	Other reserves	Retained earnings	Total attributable to owners of the parent	Non-controlling interests	Total
Equity at beginning of period at Dec. 31, 2022	$ 387	$ 35,155	$ 2,069	$ (574)	$ 37,037	$ 21	$ 37,058
Profit for the period				3,621	3,621	3	3,624
Other comprehensive income (expense)				31	31		31
Transfer to other reserves			7	(7)
Dividends				(3,047)	(3,047)		(3,047)
Issue of Ordinary Shares		8			8		8
Share-based payments charge for the period				274	274		274
Settlement of share plan awards				(532)	(532)		(532)
Net movement		8	7	340	355	3	358
Equity at end of period at Jun. 30, 2023	387	35,163	2,076	(234)	37,392	24	37,416
Equity at beginning of period at Dec. 31, 2023	388	35,188	2,065	1,502	39,143	23	39,166
Profit for the period				4,106	4,106	2	4,108
Other comprehensive income (expense)				(414)	(414)		(414)
Transfer to other reserves			13	(13)
Dividends				(3,052)	(3,052)		(3,052)
Changes in non-controlling interest						61	61
Issue of Ordinary Shares		11			11		11
Share-based payments charge for the period				307	307		307
Settlement of share plan awards				(589)	(589)		(589)
Net movement		11	13	345	369	63	432
Equity at end of period at Jun. 30, 2024	$ 388	$ 35,199	$ 2,078	$ 1,847	$ 39,512	$ 86	$ 39,598	[1]
[1] The Condensed consolidated statement of financial position as at 30 June 2024 and 30 June 2023 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2023 has been audited by PricewaterhouseCoopers LLP.

Condensed consolidated statem_5

Condensed consolidated statement of cash flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024		Jun. 30, 2023
Cash flows from operating activities
Profit before tax	$ 5,197		$ 4,350
Finance income and expense	645		654
Share of after tax losses of associates and joint ventures	19		1
Depreciation, amortisation and impairment	2,534		2,778
Movement in working capital and short-term provisions	(584)		(747)
Gains on disposal of intangible assets	(21)		(249)
Fair value movements on contingent consideration arising from business combinations	251		202
Non-cash and other movements	(550)		(594)
Cash generated from operations	7,491		6,395
Interest paid	(583)		(483)
Tax paid	(1,337)		(1,061)
Net cash inflow from operating activities	5,571		4,851
Cash flows from investing activities
Acquisition of subsidiaries, net of cash acquired	(2,771)		(189)
Payments upon vesting of employee share awards attributable to business combinations			(23)
Payment of contingent consideration from business combinations	(474)		(398)
Purchase of property, plant and equipment	(799)		(517)
Disposal of property, plant and equipment	53		126
Purchase of intangible assets	(1,474)		(1,436)
Disposal of intangible assets	75		288
Movement in profit-participation liability			175
Purchase of non-current asset investments	(67)		(26)
Disposal of non-current asset investments	51		10
Movement in short-term investments, fixed deposits and other investing instruments	42		90
Payments to associates and joint ventures	(140)
Disposal of investments in associates and joint ventures	13
Interest received	206		134
Net cash outflow from investing activities	(5,285)		(1,766)
Net cash inflow before financing activities	286		3,085
Cash flows from financing activities
Proceeds from issue of share capital	11		8
Issue of loans and borrowings	4,976		3,816
Repayment of loans and borrowings	(2,643)		(3,408)
Dividends paid	(3,050)		(3,069)
Hedge contracts relating to dividend payments	(8)		27
Repayment of obligations under leases	(150)		(129)
Movement in short-term borrowings	2,503		72
Payment of Acerta Pharma share purchase liability	(833)		(867)
Net cash inflow/(outflow) from financing activities	806		(3,550)
Net increase/(decrease) in Cash and cash equivalents in the period	1,092		(465)
Cash and cash equivalents at the beginning of the period	5,637		5,983
Exchange rate effects	(52)		(47)
Cash and cash equivalents at the end of the period	6,677		5,471
Cash and cash equivalents	6,916	[1]	5,664
Overdrafts	$ (239)		$ (193)
[1] The Condensed consolidated statement of financial position as at 30 June 2024 and 30 June 2023 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2023 has been audited by PricewaterhouseCoopers LLP.

Basis of preparation and accoun

Basis of preparation and accounting policies	6 Months Ended
	Jun. 30, 2024
Basis of preparation and accounting policies
Basis of preparation and accounting policies	Notes to the Interim financial statements ​ Note 1: Basis of preparation and accounting policies These unaudited condensed consolidated Interim financial statements for the six months ended 30 June 2024 have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards. The unaudited Interim financial statements for the six months ended 30 June 2024 were approved by the Board of Directors for publication on 25 July 2024. This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 31 December 2023 were prepared in accordance with UK-adopted international accounting standards and with the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRS Accounting Standards as issued by the IASB and International Accounting Standards as adopted by the European Union. Except for the estimation of the interim income tax charge, the Interim financial statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2023. The comparative figures for the financial year ended 31 December 2023 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the Registrar of Companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006. Going concern ​ The Group has considerable financial resources available. As at 30 June 2024, the Group has $11.8bn in financial resources (cash and cash equivalent balances of $6.9bn and undrawn committed bank facilities of $4.9bn, with $5.4bn of borrowings due within one year. These facilities contain no financial covenants and were undrawn at 30 June 2024. The $4.9bn facilities are available until April 2029. Additionally, there are a further $2.0bn undrawn committed bank facilities available until February 2025. ​ The Group’s revenues are largely derived from sales of medicines covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. Accordingly, they continue to adopt the going concern basis in preparing the Interim financial statements. Legal proceedings ​ The information contained in Note 6 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and Form 20-F Information 202 3 ​ Employee Benefit Trust ​ Following an amendment to the Employee Benefit Trust (EBT) Deed on 10th June 2024, AstraZeneca obtained control and commenced consolidation of the EBT. Going forward, cash paid on purchases of AstraZeneca Ordinary shares or American Depository Receipts, will be presented within Financing activities in the Cash flow statement. ​

Intangible assets

Intangible assets	6 Months Ended
	Jun. 30, 2024
Intangible assets
Intangible assets	Note 2: Intangible assets In accordance with IAS 36 ‘Impairment of Assets’, reviews for triggers of impairment or impairment reversals at an individual asset or cash generating unit level were conducted, and impairment tests carried out where triggers were identified. As a result, total impairment charge of $26m has been recorded against intangible assets during the six months ended 30 June 2024 (H1 2023: $320m net charge). In H1 2023, net impairment charges included the $244m impairment of the ALXN1840 intangible asset, following the decision to discontinue this development programme in Wilson’s disease. The acquisition of Icosavax, Inc. completed on 19 February 2024. The transaction is recorded as an asset acquisition based on the concentration test permitted under IFRS 3, ‘Business Combinations’, with consideration of $841m principally relating to $639m of intangible assets, $141m of cash and cash equivalents and $51m of marketable securities. Contingent consideration of up to $300m could be paid on achievement of regulatory and sales milestones; these potential liabilities would be recorded when the relevant recognition event for a regulatory or sales milestone is achieved.

Net Debt

Net Debt	6 Months Ended
	Jun. 30, 2024
Net Debt.
Net Debt	Note 3: Net debt The table below provides an analysis of Net debt and a reconciliation of Net Cash flow to the movement in Net debt. The Group monitors Net debt as part of its capital-management policy as described in Note 28 of the Annual Report and Form 20-F Information 202 3 Table 23: Net debt ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At 1 Jan ​ Cash ​ ​ ​ Non-cash ​ Exchange ​ At 30 Jun ​ ​ 2024 ​ flow ​ Acquisitions ​ & other ​ movements ​ 2024 ​ $m $m $m ​ $m $m $m Non-current instalments of loans (22,365) ​ (4,973) ​ (3) ​ (2) ​ 118 ​ (27,225) Non-current instalments of leases ​ (857) ​ - ​ (12) ​ (97) ​ 17 ​ (949) Total long-term debt (23,222) ​ (4,973) ​ (15) ​ (99) ​ 135 ​ (28,174) Current instalments of loans (4,614) ​ 2,583 ​ (9) ​ (5) ​ 27 ​ (2,018) Current instalments of leases (271) ​ 174 ​ (6) ​ (197) ​ 8 ​ (292) Commercial paper ​ - ​ (2,453) ​ - ​ - ​ - ​ (2,453) Collateral received from derivative counterparties (215) ​ 13 ​ - ​ - ​ - ​ (202) Other short-term borrowings excluding overdrafts ​ (97) ​ (63) ​ - ​ - ​ 5 ​ (155) Overdrafts (203) ​ (35) ​ - ​ - ​ (1) ​ (239) Total current debt ​ (5,400) ​ 219 ​ (15) ​ (202) ​ 39 ​ (5,359) Gross borrowings ​ (28,622) ​ (4,754) ​ (30) ​ (301) ​ 174 ​ (33,533) Net derivative financial instruments ​ 150 ​ 65 ​ - ​ (82) ​ - ​ 133 Net borrowings ​ (28,472) ​ (4,689) ​ (30) ​ (383) ​ 174 ​ (33,400) Cash and cash equivalents ​ 5,840 ​ 885 ​ 242 ​ - ​ (51) ​ 6,916 Other investments - current ​ 122 ​ (42) ​ 87 ​ - ​ (7) ​ 160 Cash and investments ​ 5,962 ​ 843 ​ 329 ​ - ​ (58) ​ 7,076 Net debt ​ (22,510) ​ (3,846) ​ 299 ​ (383) ​ 116 ​ (26,324) ​ Net debt increased by $3,814m in the half year to $26,324m. Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. Non-cash movements in the period include fair value adjustments under IFRS 9 ‘Financial Instruments’. ​ In February 2024, AstraZeneca issued the following: ​ - $1,250 m of fixed-rate notes with a coupon of 4.8% maturing in February 2027 - $1,250 m of fixed-rate notes with a coupon of 4.85% maturing in February 2029 - $1,000 m of fixed-rate notes with a coupon of 4.9% maturing in February 2031 - $1,500 m of fixed-rate notes with a coupon of 5% maturing in February 2034 ​ AstraZeneca repaid two bonds of carrying value $2,569m in Q2 2024 included in the cash outflow from Repayment of loans and borrowings of $2,643m. AstraZeneca also issued Commercial paper during the half year and the balance as at 30 June 2024 is $2,453m (H1 2023: $nil). The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral on financial derivatives, for the benefit of the other, equivalent to the market valuation of the derivative positions above a predetermined threshold. The carrying value of such cash collateral held by the Group at 30 June 2024 was $202m (31 December 2023: $215m) and the carrying value of such cash collateral posted by the Group at 30 June 2024 was $97m (31 December 2023: $102m). The equivalent GAAP measure to Net debt is ‘liabilities arising from financing activities’, which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above and includes the Acerta Pharma share purchase liability of $nil (31 December 2023: $833m). During the six months ended 30 June 2024, there have been no changes to the Company’s solicited long term credit ratings. Moody’s credit ratings were long term: A2; short term: P-1. Standard and Poor’s credit ratings were long term: A; short term: A-1

Financial instruments

Financial instruments	6 Months Ended
	Jun. 30, 2024
Financial instruments
Financial instruments	Note 4: Financial Instruments As detailed in the Group’s most recent annual financial statements, the principal financial instruments consist of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables, lease liabilities and interest-bearing loans and borrowings. ​ The Group has certain equity investments that are categorised as Level 3 in the fair value hierarchy that are held at $337m (31 December 2023: $313m) and for which a fair value gain of $1m has been recognised in the six months ended 30 June 2024 (H1 2023: $1m). In the absence of specific market data, these unlisted investments are held at fair value based on the cost of investment and adjusted as necessary for impairments and revaluations on new funding rounds, which are seen to approximate the fair value. All other fair value gains and/or losses that are presented in Net gains/(losses) on equity investments measured at fair value through other comprehensive income in the Condensed consolidated statement of comprehensive income for the six months ended 30 June 2024 are Level 1 fair value measurements, valued based on quoted prices in active markets. ​ Financial instruments measured at fair value include $1,670m of other investments, $5,463m held in money-market funds, and $133m of derivatives as at 30 June 2024. With the exception of derivatives being Level 2 fair valued, and certain equity instruments of $350m categorised as Level 3, the aforementioned balances are Level 1 fair valued. Financial instruments measured at amortised cost include $97m of cash collateral pledged to counterparties. The total fair value of interest-bearing loans and borrowings at 30 June 2024, which have a carrying value of $33,533m in the Condensed consolidated statement of financial position, was $32,231m. ​ Table 24: Financial instruments – contingent consideration ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2024 ​ 2023 ​ ​ Diabetes ​ ​ ​ ​ ​ ​ ​ alliance Other Total Total ​ ​ $m ​ $m ​ $m ​ $m At 1 January 1,945 ​ 192 ​ 2,137 ​ 2,222 Additions through business combinations ​ - ​ 198 ​ 198 ​ 60 Settlements (473) ​ (1) ​ (474) ​ (398) Revaluations ​ 220 ​ 31 ​ 251 ​ 202 Discount unwind 50 ​ 7 ​ 57 ​ 66 At 30 June 1,742 ​ 427 ​ 2,169 ​ 2,152 ​ Contingent consideration arising from business combinations is fair valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues. ​ The contingent consideration balance relating to BMS’s share of the global diabetes alliance of $1,742m (31 December 2023: $1,945m) would increase/decrease by $174m with an increase/decrease in sales of 10%, as compared with the current estimates.

Business combinations

Business combinations	6 Months Ended
	Jun. 30, 2024
Business combinations
Business combinations	Note 5: Business combinations Gracell ​ On 22 February 2024, AstraZeneca completed the acquisition of Gracell Biotechnologies Inc. (Gracell), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases. Gracell will operate as a wholly owned subsidiary of AstraZeneca, with operations in China and the US. ​ The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with AZD0120 (formerly GC012F), a novel, clinical-stage T-cell (CAR-T: therapeutic chimeric antigen receptor) therapy. AZD0120 is a potential new treatment for multiple myeloma, as well as other haematologic malignancies and autoimmune diseases, including Systemic Lupus Erythematosus (SLE). ​ The transaction is recorded as a business combination using the acquisition method of accounting in accordance with IFRS 3 ‘Business Combinations’. Consequently, the assets acquired, and liabilities assumed are recorded at fair value. Due to the proximity of the acquisition to the reporting date, the purchase price allocation exercise under IFRS 3 is in process, with the following items disclosed on a provisional basis. ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair values ​ ​ $m Intangible assets ​ 1,038 Cash and cash equivalents ​ 212 Net deferred tax liability ​ (260) Other immaterial balances ​ (89) Total net assets acquired ​ 901 Goodwill ​ 136 Consideration ​ 1,037 ​ The total consideration fair value of $1,037m includes cash consideration of $983m and future regulatory milestone-based consideration of $54m. Intangible assets recognised relate to products in development, principally AZD0120, and were fair valued using the multi-period excess earnings method, which uses several estimates regarding the amount and timing of future cash flows. The key assumptions in the cash flows are PTRS, peak year sales and revenue erosion profiles. ​ The net deferred tax liability of $260m principally arises from the deferred tax impact of the uplift in fair value of intangible assets. ​ Goodwill of $136m has been recognised, which principally comprises the premium attributable to the core technological capabilities and knowledge base of the company. Goodwill is not expected to be deductible for tax purposes. ​ Gracell’s results have been consolidated into the Group’s results from 22 February 2024. ​ Fusion On 4 June 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals Inc., (Fusion) a clinical-stage biopharmaceutical company developing next-generation radioconjugates. The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. As a result of the acquisition, Fusion became a wholly owned subsidiary of AstraZeneca, with operations in Canada and the US. ​ This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of radioconjugates, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based radioconjugates to AstraZeneca. ​ The transaction is recorded as a business combination using the acquisition method of accounting in accordance with IFRS 3 ‘Business Combinations’. Consequently, the assets acquired, and liabilities assumed are recorded at fair value. Due to the proximity of the acquisition to the reporting date, the purchase price allocation exercise under IFRS 3 is in process, with the following items disclosed on a provisional basis. ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair values ​ ​ $m Intangible assets ​ 1,326 Cash and cash equivalents ​ 30 Current investments ​ 87 Net deferred tax liability ​ (246) Other immaterial balances ​ 51 Total net assets acquired ​ 1,248 Goodwill ​ 947 Consideration ​ 2,195 ​ The total consideration fair value of $2,195m includes cash consideration of $2,051m and future regulatory milestone-based consideration of $144m. Intangible assets relating to products in development comprise the FPI-2265 ($848m), FPI-2059 ($165m) and AZD2068 ($313m) programmes. These were fair valued using the multi-period excess earnings method, which uses several estimates regarding the amount and timing of future cash flows. The key assumptions in the cash flows are PTRS, peak year sales and revenue erosion profiles. ​ The net deferred tax liability of $246m principally arises from the deferred tax impact of the uplift in fair value of intangible assets. ​ Goodwill recognised comprises a number of not individually quantifiable elements. These include the premium attributable to a pre-existing well positioned business in the innovation intensive biopharmaceuticals market with a highly skilled workforce, unidentified potential products that future research and development may yield, and the core capabilities and knowledge base of the company including radioisotope supply and manufacturing expertise. Goodwill is not expected to be deductible for tax purposes. ​ Immediately prior to the acquisition, AstraZeneca held an approximately 1% shareholding in Fusion considered to have a fair value of $24m. ​ Fusion’s results have been consolidated into the Group’s results from 4 June 2024.

Legal proceedings and contingen

Legal proceedings and contingent liabilities	6 Months Ended
	Jun. 30, 2024
Legal proceedings and contingent liabilities
Legal proceedings and contingent liabilities	Note 6: Legal proceedings and contingent liabilities AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations, including Government investigations, relating to product liability, commercial disputes, infringement of intellectual property (IP) rights, the validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual Report and Form 20-F Information 2023 (the Disclosures). Information about the nature and facts of the cases is disclosed in accordance with IAS 37. ​ As discussed in the Disclosures, the majority of claims involve highly complex issues. Often these issues are subject to substantial uncertainties and, therefore, the probability of a loss, if any, being sustained and/or an estimate of the amount of any loss is difficult to ascertain. ​ In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the expected loss. The position could change over time and the estimates that the Company made, and upon which the Company have relied in calculating these provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors causing this uncertainty are described more fully in the Disclosures and herein. ​ AstraZeneca has full confidence in, and will vigorously defend and enforce, its IP. Matters disclosed in respect of the second quarter of 2024 and to 25 July 2024 Patent litigation Legal proceedings brought against AstraZeneca considered to be contingent liabilities ​ Enhertu US patent proceedings In October 2020, Seagen Inc. (Seagen) filed a complaint against Daiichi Sankyo Company, Limited (Daiichi Sankyo) in the US District Court for the Eastern District of Texas (District Court) alleging that Enhertu Enhertu Enhertu ​ In December 2020 and January 2021, AstraZeneca and Daiichi Sankyo, Inc. filed post-grant review (PGR) petitions with the US Patent and Trademark Office (USPTO) alleging, among other things, that the Seagen patent is invalid for lack of written description and enablement. The USPTO initially declined to institute the PGRs, but, in April 2022, the USPTO granted the rehearing requests and instituted both PGR petitions. Seagen subsequently disclaimed all patent claims at issue in one of the PGR proceedings. In July 2022, the USPTO reversed its institution decision and declined to institute the other PGR petition. AstraZeneca and Daiichi Sankyo, Inc. requested reconsideration of the decision not to institute review of the patent. In February 2023, the USPTO reinstituted the PGR proceeding. In February 2024, the USPTO issued a decision that the claims were unpatentable. Seagen has appealed this decision. ​ Tagrisso US patent proceedings In September 2021, Puma Biotechnology, Inc. (Puma) and Wyeth LLC (Wyeth) filed a patent infringement lawsuit in the US District Court for the District of Delaware (District Court) against AstraZeneca relating to Tagrisso ​ Legal proceedings brought by AstraZeneca considered to be contingent assets ​ Calquence US patent proceedings In February 2022, in response to Paragraph IV notices from multiple ANDA filers, AstraZeneca filed patent infringement lawsuits in the US District Court for the District of Delaware (District Court). In its complaint, AstraZeneca alleged that a generic version of Calquence Calquence ​ In April 2024, AstraZeneca received a Paragraph IV notice from an ANDA filer relating to patents listed in the FDA Orange Book with reference to Calquence Calquence ​ ​ Lokelma US patent proceedings In August 2022, in response to Paragraph IV notices, AstraZeneca initiated ANDA litigation against multiple generic filers in the US District Court for the District of Delaware (District Court). AstraZeneca alleged that a generic version of Lokelma ​ AstraZeneca entered into separate settlement agreements with two generic manufacturers which resulted in dismissal of the corresponding litigations. Additional proceedings with the remaining generic manufacturers are ongoing in the District Court. Trial is scheduled for March 2025. ​ Lynparza US patent proceedings In December 2022, AstraZeneca received a Paragraph IV notice from Natco Pharma Limited (Natco) relating to Lynparza Lynparza ​ In December 2023, AstraZeneca received a Paragraph IV notice from Sandoz Inc. (Sandoz) relating to Lynparza Lynparza ​ In May 2024, AstraZeneca filed additional ANDA actions against Natco and Sandoz asserting recently issued patents covering Lynparza. ​ In May 2024, AstraZeneca received a Paragraph IV notice from Cipla USA, Inc. and Cipla Limited (collectively, Cipla) relating to Lynparza Lynparza, ​ Soliris US patent proceedings In January 2024, Alexion initiated patent infringement litigation against Samsung Bioepis Co. Ltd. (Samsung) in the US District Court for the District of Delaware alleging that Samsung’s biosimilar eculizumab Soliris inter partes A eculizumab ​ European patent proceedings In March 2024, Alexion filed motions for provisional measures against Amgen Pharmaceuticals Inc (Amgen) and Samsung Bioepis Co. Ltd. (Samsung) and their respective affiliates at the Hamburg Local Division of the Unified Patent Court on the basis that Amgen’s and Samsung’s biosimilar eculizumab products infringe an Alexion patent. In June 2024 the UPC denied the requested provisional measures. Alexion has appealed this decision. In parallel, Samsung has filed opposition to the patent at the European Patent Office. ​ UK patent proceedings In May 2024, Alexion initiated patent infringement proceedings against Amgen Ltd and Samsung Bioepis UK Ltd (Samsung UK) in the UK High Court of Justice alleging that their respective biosimilar eculizumab products infringe an Alexion patent; on the same day, Samsung UK initiated a revocation action for the same patent. Trial has been scheduled for March 2025. ​ Tagrisso Russia patent proceedings In Russia, in August 2023, AstraZeneca filed lawsuits in the Arbitration Court of the Moscow Region (Court) against the Ministry of Health of the Russian Federation and Axelpharm LLC (Axelpharm) related to Axelpharm’s improper use of AstraZeneca’s information to obtain authorisation to market a generic version of Tagrisso ​ In Russia, in November 2023, Axelpharm filed a compulsory licensing action against AstraZeneca in the Court related to a patent that covers Tagrisso ​ In July 2024, AstraZeneca filed a patent infringement lawsuit and an unfair competition claim with the Federal Anti-Monopoly Service of Russia against AxelPharm and others related to the securing of state contracts in Russia for its generic version of osimertinib ​ Commercial litigation Legal proceedings brought against AstraZeneca considered to be contingent liabilities ​ Anti-Terrorism Act Civil Lawsuit US proceedings In the US, in October 2017, AstraZeneca and certain other pharmaceutical and/or medical device companies were named as defendants in a complaint filed in the US District Court for the District of Columbia (District Court) by US nationals (or their estates, survivors, or heirs) who were killed or wounded in Iraq between 2005 and 2013. The plaintiffs allege that the defendants violated the US Anti-Terrorism Act and various state laws by selling pharmaceuticals and medical supplies to the Iraqi Ministry of Health. In July 2020, the District Court granted AstraZeneca’s and the other defendants’ motion to dismiss the lawsuit, which the DC Circuit Court of Appeals (the Appellate Court) reversed in January 2022. In June 2024, the United States Supreme Court issued an order vacating the 2022 decision and granted AstraZeneca’s and the other defendants’ request for a remand to the Appellate Court for reconsideration under new case law. ​ Employment Litigation US proceedings In December 2022, AstraZeneca was served with a lawsuit filed by seven former employees in the US District Court for the District of Delaware (District Court) asserting claims of discrimination on grounds of age and religion, related to AstraZeneca’s vaccination requirement. In March 2023, AstraZeneca filed a partial motion to dismiss certain religious discrimination claims and a motion to strike the class and collective claims. In September 2023, Plaintiffs moved for conditional certification of the collective action. In June 2024, the District Court granted AstraZeneca’s partial motion to dismiss, granted AstraZeneca’s motion to strike, and denied without prejudice Plaintiff’s motion for conditional certification. ​ Pay Equity Litigation US proceedings AstraZeneca is defending a putative class and collective action in the US District Court for the Northern District of Illinois (District Court) brought by three named plaintiffs, who are former AstraZeneca employees. The case involves claims under the federal and Illinois Equal Pay Acts, with the plaintiffs alleging they were paid less than male employees who performed substantially similar and/or equal work. In May 2024, the District Court conditionally certified a collective under the federal Equal Pay Act and authorised the sending of notice to potential collective action members. The notice was distributed in June 2024. ​ University of Sheffield Contract Dispute UK proceedings In June 2024, AstraZeneca was served with a lawsuit filed by the University of Sheffield (Sheffield). In its complaint, Sheffield alleges that AstraZeneca made misrepresentations to induce Sheffield to amend a patent license relating to Lynparza. AstraZeneca is considering its response ​ Viela Bio, Inc. Shareholder Litigation US proceedings In February 2023, AstraZeneca was served with a lawsuit filed in Delaware state court against AstraZeneca and certain officers (collectively, Defendants), on behalf of a putative class of Viela Bio, Inc. (Viela) shareholders. The complaint alleged that the Defendants breached their fiduciary duty to Viela shareholders in the course of Viela’s 2021 merger with Horizon Therapeutics, plc. In July 2024, the Court granted with prejudice AstraZeneca’s motion to dismiss. ​ Financial State me nts Legal proceedings brought by AstraZeneca considered to be contingent assets ​ PARP Inhibitor Royalty Dispute UK proceedings In October 2012, Tesaro, Inc. (now wholly owned by GlaxoSmithKline plc, (GSK)) entered into two worldwide, royalty-bearing patent license agreements with AstraZeneca related to GSK’s product niraparib niraparib ​ Government investigations/proceedings Legal proceedings brought against AstraZeneca considered to be contingent liabilities ​ Boston US Attorney Investigation US Proceedings In June 2024, AstraZeneca was served with a subpoena issued by the US Attorney’s Office in Boston, seeking documents and information relating to payments by AstraZeneca to healthcare providers. AstraZeneca is cooperating with this enquiry. ​ Turkish Ministry of Health Matter Turkey proceedings In Turkey, in July 2020, the Turkish Ministry of Health (Ministry of Health) initiated an investigation regarding payments to healthcare providers by Alexion and former employees and consultants. The investigation arose from Alexion’s disclosure of a $21.5m civil settlement with the US Securities & Exchange Commission (SEC) in July 2020 fully resolving the SEC’s investigation into possible violations of the US Foreign Corrupt Practices Act. In September 2021, the Ministry of Health completed its draft investigation report, and referred the matter to the Ankara Public Prosecutor’s Office with a recommendation for further proceedings against certain former employees. In June 2024, the Ankara Public Prosecutor’s Office closed its investigation without further action. ​ Legal proceedings brought by AstraZeneca considered to be contingent assets ​ Inflation Reduction Act Litigation US proceedings In August 2023, AstraZeneca filed a lawsuit in the US District Court for the District of Delaware (District Court) against the US Department of Health and Human Services (HHS) challenging aspects of the drug price negotiation provisions of the Inflation Reduction Act and the implementing guidance and regulations. In March 2024, the District Court granted HHS’ motions and dismissed AstraZeneca’s lawsuit. AstraZeneca has appealed the District Court’s decision. ​ 340B State Litigation US proceedings AstraZeneca has filed lawsuits against Arkansas, Kansas, Louisiana, Maryland, Minnesota, Mississippi, and West Virginia challenging the constitutionality of each state’s 340B statute. In the Arkansas matter, trial is scheduled for April 2025. In the Louisiana matter, AstraZeneca and the state have filed motions for summary judgment and a hearing was held in June 2024. The remaining matters are in their preliminary stages. ​ Other Additional government inquiries As is true for most, if not all, major prescription pharmaceutical companies, AstraZeneca is currently involved in multiple inquiries into drug marketing and pricing practices. In addition to the investigations described above, various law enforcement offices have, from time to time, requested information from the Group. There have been no material developments in those matters. ​ ​ Matters disclosed in respect of the first quarter of 2024 and to 25 April 2024 ​ Patent litigation ​ Legal proceedings brought against AstraZeneca considered to be contingent liabilities ​ Forxiga UK patent proceedings In the UK, one of AstraZeneca’s patents relating to Forxiga ​ Tagrisso US patent proceedings In September 2021, Puma Biotechnology, Inc. (Puma) and Wyeth LLC (Wyeth) filed a patent infringement lawsuit in the US District Court for the District of Delaware (District Court) against AstraZeneca relating to Tagrisso ​ Legal proceedings brought by AstraZeneca considered to be contingent assets ​ Calquence US patent proceedings In February 2022, in response to Paragraph IV notices from multiple ANDA filers, AstraZeneca filed patent infringement lawsuits in the US District Court for the District of Delaware (District Court). In its complaint, AstraZeneca alleged that a generic version of Calquence ​ In March and April 2024, AstraZeneca entered into settlement agreements with generic manufacturers, Sandoz Inc., and Natco Pharma Limited with Natco Pharma Inc., resulting in dismissal of the corresponding Calquence Calquence ​ In April 2024, AstraZeneca received a Paragraph IV notice from an ANDA filer relating to patents listed in the FDA Orange Book with reference to Calquence ​ Lokelma US patent proceedings In August 2022, in response to Paragraph IV notices, AstraZeneca initiated ANDA litigation against multiple generic filers in the US District Court for the District of Delaware (District Court). Trial is scheduled for March 2025. ​ AstraZeneca entered into a settlement agreement with a generic manufacturer, Alkem Laboratories, which resulted in dismissal of the corresponding litigation. Additional proceedings with the remaining generic manufacturers are ongoing in the District Court. ​ Soliris US patent proceedings In January 2024, Alexion initiated patent infringement litigation against Samsung Bioepis Co. Ltd. (Samsung) in the US District Court for the District of Delaware alleging that Samsung’s biosimilar eculizumab product, for which Samsung is currently seeking FDA approval, will infringe six Soliris ​ European patent proceedings In March 2024, Alexion filed motions for preliminary injunctions against Amgen and Samsung at the Hamburg Local Division of the Unified Patent Court on the basis that Amgen’s and Samsung’s biosimilar eculizumab products infringe Alexion’s eculizumab molecule patent that is expected to grant in Q2 2024. No hearing date for the preliminary injunction motions has been set. ​ Tagrisso Russia patent proceedings In Russia, in August 2023, AstraZeneca filed lawsuits in the Arbitration Court of the Moscow Region (Court) against the Ministry of Health of the Russian Federation and Axelpharm LLC (Axelpharm) related to Axelpharm’s improper use of AstraZeneca’s information to obtain authorisation to market a generic version of Tagrisso ​ In Russia, in November 2023, Axelpharm filed a compulsory licensing action against AstraZeneca in the Court related to a patent that covers Tagrisso ​ Product liability litigation Legal proceedings brought against AstraZeneca for which a provision has been taken ​ Nexium and Losec / Prilosec US proceedings AstraZeneca has been defending lawsuits brought in federal and state courts involving claims that plaintiffs have been diagnosed with various injuries following treatment with proton pump inhibitors (PPIs), including Nexium and Prilosec. Most of the lawsuits alleged kidney injury. In August 2017, the pending federal court cases were consolidated into a multidistrict litigation (MDL) proceeding in the US District Court for the District of New Jersey for pre-trial purposes. Cases alleging kidney injury were also filed in Delaware and New Jersey state courts. ​ In addition, AstraZeneca has been defending lawsuits involving allegations of gastric cancer following treatment with PPIs, including one such claim in the US District Court for the Middle District of Louisiana (Louisiana District Court). ​ In October 2023, AstraZeneca resolved all pending claims in the MDL, as well as all pending claims in Delaware and New Jersey state courts, for $425m, for which a provision has been taken. The only remaining case is the one pending in the Louisiana District Court, which is scheduled for trial in January 2025. ​ Canada proceedings In Canada, in July and August 2017, AstraZeneca was served with three putative class action lawsuits. Two of the lawsuits have been dismissed, one in 2019 and one in 2021. The third lawsuit seeks authorisation to represent individual residents in Canada who allegedly suffered kidney injuries from the use of proton pump inhibitors, including Nexium ​ Legal proceedings brought against AstraZeneca considered to be contingent liabilities ​ Onglyza and Kombiglyze US proceedings In the US, AstraZeneca has been defending various lawsuits in both California state court and in a consolidated federal proceeding alleging heart failure, cardiac injuries, and/or death from treatment with Onglyza Kombiglyze ​ Vaxzevria UK proceedings AstraZeneca is defending lawsuits in the UK involving multiple claimants alleging injuries following vaccination with AstraZeneca’s COVID-19 vaccine. Most of the lawsuits involve claims of thrombosis with thrombocytopenia syndrome. No trial dates have been scheduled. ​ Commercial litigation Legal proceedings brought against AstraZeneca considered to be contingent liabilities ​ 340B Antitrust Litigation US proceedings In September 2021, AstraZeneca was served with a class-action antitrust complaint filed in the US District Court for the Western District of New York (District Court) by Mosaic Health alleging a conspiracy to restrict access to 340B discounts in the diabetes market through contract pharmacies. In September 2022, the District Court granted AstraZeneca’s motion to dismiss the Complaint. In February 2024, the District Court denied Plaintiffs’ request to file an amended complaint and entered an order closing the matter. In March 2024, Plaintiffs filed an appeal. ​ Definiens Germany proceedings In Germany, in July 2020, AstraZeneca received a notice of arbitration filed with the German Institution of Arbitration from the sellers of Definiens AG (the Sellers) regarding the 2014 Share Purchase Agreement (SPA) between AstraZeneca and the Sellers. The Sellers claim that they are owed approximately $140m in earn-outs under the SPA. In December 2023, after an arbitration hearing, the arbitration panel made a final award of $46.43m in favour of the Sellers. In March 2024, AstraZeneca filed an application with the Bavarian Supreme Court to set aside the arbitration award. ​ Financial State me nts Legal proceedings brought by AstraZeneca considered to be contingent assets ​ PARP Inhibitor Royalty Dispute UK proceedings In October 2012, Tesaro, Inc. (now wholly owned by GlaxoSmithKline plc, (GSK)) entered into two worldwide, royalty-bearing patent license agreements with AstraZeneca related to GSK’s product niraparib niraparib ​ Government investigations/proceedings Legal proceedings brought against AstraZeneca considered to be contingent liabilities ​ 340B Qui Tam US proceedings In July 2023, AstraZeneca was served with an unsealed civil lawsuit brought by a qui tam relator on behalf of the United States, several states, and the District of Columbia in the US District Court for the Central District of California (District Court). The complaint alleges that AstraZeneca violated the US False Claims Act and state law analogues. In March 2024, the District Court granted AstraZeneca’s motion to dismiss the First Amended Complaint without leave to amend. In April 2024, the relator filed an appeal. ​ Legal proceedings brought by AstraZeneca considered to be contingent assets ​ Inflation Reduction Act Litigation US proceedings In August 2023, AstraZeneca filed a lawsuit in the US District Court for the District of Delaware (District Court) against the US Department of Health and Human Services (HHS) challenging aspects of the drug price negotiation provisions of the Inflation Reduction Act and the implementing guidance and regulations. In March 2024, the District Court granted HHS’ motions and dismissed AstraZeneca’s lawsuit. ​ Arkansas 340B Litigation US proceedings In March 2024, AstraZeneca filed a lawsuit against the State of Arkansas alleging that the Arkansas’s 340B statute is preempted by federal law and unconstitutional. ​ Other Additional government inquiries As is true for most, if not all, major prescription pharmaceutical companies, AstraZeneca is currently involved in multiple inquiries into drug marketing and pricing practices. In addition to the investigations described above, various law enforcement offices have, from time to time, requested information from the Group. There have been no material developments in those matters. ​

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events
Subsequent Events	Note 7 : Subsequent events ​ On 15 July 2024, AstraZeneca completed the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. AstraZeneca acquired all outstanding equity of Amolyt for a total consideration of up to $1.05 billion, on a cash and debt free basis. This includes an initial payment of $800m on deal closing, subject to customary closing adjustments, and a further up to $250m in contingent milestones-based consideration. Due to the timing of the transaction post period end, the accounting and other disclosures will be finalised in the second half of 2024. ​ ​

H1 2024 - Product Sales year-on

H1 2024 - Product Sales year-on-year analysis	6 Months Ended
	Jun. 30, 2024
H1 2024 - Product Sales year-on-year analysis
H1 2024 - Product Sales year-on-year analysis	Table 25: H1 2024 - Product Sales year-on-year analysis 15 The CER information in respect of H1 2024 included in the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ World ​ US ​ Emerging Markets ​ Europe ​ Established RoW ​ $m Act % chg CER % chg ​ $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 9,737 ​ 17 ​ 21 ​ 4,387 ​ 20 ​ 2,300 ​ 18 ​ 28 ​ 1,967 ​ 25 ​ 23 ​ 1,083 ​ (2) ​ 8 Tagrisso 3,203 ​ 10 ​ 13 ​ 1,282 ​ 16 ​ 919 ​ 8 ​ 16 ​ 628 ​ 16 ​ 15 ​ 374 ​ (11) ​ (2) Imfinzi 2,259 ​ 20 ​ 25 ​ 1,202 ​ 17 ​ 245 ​ 35 ​ 58 ​ 459 ​ 38 ​ 36 ​ 353 ​ 7 ​ 19 Calquence ​ 1,508 ​ 27 ​ 28 ​ 1,048 ​ 21 ​ 75 ​ 82 ​ n/m ​ 320 ​ 42 ​ 41 ​ 65 ​ 30 ​ 34 Lynparza ​ 1,450 ​ 6 ​ 9 ​ 607 ​ 5 ​ 320 ​ 15 ​ 26 ​ 398 ​ 9 ​ 8 ​ 125 ​ (14) ​ (6) Enhertu ​ 249 ​ n/m ​ n/m ​ - ​ - ​ 161 ​ n/m ​ n/m ​ 57 ​ n/m ​ n/m ​ 31 ​ n/m ​ n/m Zoladex ​ 549 ​ 19 ​ 27 ​ 8 ​ 20 ​ 415 ​ 22 ​ 31 ​ 77 ​ 16 ​ 14 ​ 49 ​ 2 ​ 12 Imjudo ​ 136 ​ 35 ​ 38 ​ 88 ​ 30 ​ 7 ​ n/m ​ n/m ​ 16 ​ n/m ​ n/m ​ 25 ​ (5) ​ 6 Truqap ​ 142 ​ n/m ​ n/m ​ 141 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ 1 ​ n/m ​ n/m Orpathys ​ 25 ​ 14 ​ 19 ​ - ​ - ​ 25 ​ 14 ​ 19 ​ - ​ - ​ - ​ - ​ - ​ - Others 216 ​ (21) ​ (15) ​ 11 ​ 6 ​ 133 ​ (21) ​ (15) ​ 12 ​ (36) ​ (36) ​ 60 ​ (21) ​ (12) BioPharmaceuticals: CVRM 6,164 ​ 18 ​ 22 ​ 1,483 ​ 16 ​ 2,749 ​ 17 ​ 24 ​ 1,559 ​ 33 ​ 32 ​ 373 ​ (8) ​ 2 Farxiga ​ 3,785 ​ 35 ​ 38 ​ 867 ​ 37 ​ 1,474 ​ 37 ​ 44 ​ 1,233 ​ 45 ​ 44 ​ 211 ​ (15) ​ (5) Brilinta ​ 665 ​ - ​ 2 ​ 354 ​ (1) ​ 166 ​ 4 ​ 14 ​ 136 ​ - ​ (1) ​ 9 ​ (26) ​ (19) Crestor ​ 589 ​ 1 ​ 6 ​ 22 ​ (18) ​ 475 ​ 4 ​ 9 ​ 22 ​ (30) ​ (29) ​ 70 ​ 3 ​ 13 Seloken / Toprol-XL 315 ​ (8) ​ (1) ​ - ​ n/m ​ 307 ​ (8) ​ (1) ​ 6 ​ 4 ​ 7 ​ 2 ​ (39) ​ (37) Lokelma 249 ​ 26 ​ 30 ​ 115 ​ 10 ​ 42 ​ 75 ​ 83 ​ 41 ​ 62 ​ 61 ​ 51 ​ 16 ​ 31 roxadustat 163 ​ 22 ​ 27 ​ - ​ - ​ 163 ​ 22 ​ 27 ​ - ​ - ​ - ​ - ​ n/m ​ n/m Andexxa ​ 105 ​ 18 ​ 21 ​ 42 ​ 14 ​ 2 ​ n/m ​ n/m ​ 40 ​ 38 ​ 36 ​ 21 ​ (9) ​ 4 Wainua ​ 21 ​ n/m ​ n/m ​ 21 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Others 272 ​ (30) ​ (28) ​ 62 ​ (50) ​ 120 ​ (27) ​ (22) ​ 81 ​ (10) ​ (10) ​ 9 ​ (7) ​ (5) BioPharmaceuticals: R&I 3,601 ​ 17 ​ 20 ​ 1,567 ​ 21 ​ 1,032 ​ 16 ​ 23 ​ 680 ​ 17 ​ 16 ​ 322 ​ 7 ​ 12 Symbicort 1,491 ​ 16 ​ 19 ​ 598 ​ 38 ​ 450 ​ 11 ​ 21 ​ 286 ​ - ​ (1) ​ 157 ​ (4) ​ (2) Fasenra 781 ​ 5 ​ 6 ​ 478 ​ 2 ​ 41 ​ 45 ​ 53 ​ 192 ​ 9 ​ 8 ​ 70 ​ (2) ​ 6 Pulmicort ​ 379 ​ 10 ​ 14 ​ 8 ​ (53) ​ 317 ​ 16 ​ 22 ​ 37 ​ 1 ​ (1) ​ 17 ​ (13) ​ (9) Breztri ​ 454 ​ 48 ​ 51 ​ 225 ​ 37 ​ 131 ​ 61 ​ 69 ​ 65 ​ 80 ​ 79 ​ 33 ​ 33 ​ 44 Tezspire ​ 100 ​ n/m ​ n/m ​ - ​ - ​ 5 ​ n/m ​ n/m ​ 61 ​ n/m ​ n/m ​ 34 ​ n/m ​ n/m Saphnelo ​ 203 ​ 77 ​ 77 ​ 184 ​ 71 ​ 2 ​ n/m ​ n/m ​ 10 ​ n/m ​ n/m ​ 7 ​ 86 ​ 91 Airsupra 21 ​ n/m ​ n/m ​ 21 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Others 172 ​ (27) ​ (26) ​ 53 ​ (47) ​ 86 ​ (18) ​ (14) ​ 29 ​ 3 ​ 2 ​ 4 ​ (12) ​ (10) BioPharmaceuticals: V&I 324 ​ (27) ​ (24) ​ 55 ​ n/m ​ 131 ​ (12) ​ (7) ​ 81 ​ (28) ​ (30) ​ 57 ​ (68) ​ (65) Synagis ​ 253 ​ (11) ​ (6) ​ (1) ​ n/m ​ 131 ​ 4 ​ 10 ​ 67 ​ (27) ​ (29) ​ 56 ​ (15) ​ (6) Beyfortus ​ 54 ​ n/m ​ n/m ​ 53 ​ n/m ​ - ​ - ​ - ​ - ​ (81) ​ (61) ​ 1 ​ n/m ​ n/m FluMist ​ 8 ​ n/m ​ n/m ​ 3 ​ n/m ​ - ​ - ​ - ​ 5 ​ n/m ​ 97 ​ - ​ n/m ​ n/m COVID-19 mAbs ​ 3 ​ (98) ​ (98) ​ - ​ - ​ - ​ n/m ​ n/m ​ 3 ​ (58) ​ (59) ​ - ​ n/m ​ n/m Others ​ 6 ​ (79) ​ (80) ​ - ​ - ​ - ​ n/m ​ n/m ​ 6 ​ (41) ​ (43) ​ - ​ n/m ​ n/m Rare Disease 4,243 ​ 11 ​ 15 ​ 2,517 ​ 10 ​ 454 ​ 40 ​ 70 ​ 794 ​ 3 ​ 2 ​ 478 ​ 9 ​ 20 Ultomiris 1,804 ​ 32 ​ 35 ​ 1,032 ​ 27 ​ 66 ​ n/m ​ n/m ​ 411 ​ 32 ​ 31 ​ 295 ​ 42 ​ 58 Soliris ​ 1,439 ​ (13) ​ (8) ​ 808 ​ (9) ​ 255 ​ 19 ​ 54 ​ 260 ​ (29) ​ (30) ​ 116 ​ (33) ​ (30) Strensiq ​ 653 ​ 16 ​ 18 ​ 529 ​ 17 ​ 31 ​ 30 ​ 47 ​ 48 ​ 14 ​ 12 ​ 45 ​ 4 ​ 15 Koselugo 247 ​ 55 ​ 64 ​ 101 ​ 13 ​ 83 ​ n/m ​ n/m ​ 45 ​ 95 ​ 92 ​ 18 ​ n/m ​ n/m Kanuma ​ 100 ​ 17 ​ 20 ​ 47 ​ 18 ​ 19 ​ 7 ​ 20 ​ 30 ​ 24 ​ 25 ​ 4 ​ 11 ​ 20 Other medicines ​ 560 ​ (9) ​ (2) ​ 52 ​ (24) ​ 385 ​ (1) ​ 8 ​ 53 ​ 10 ​ 10 ​ 70 ​ (35) ​ (29) Nexium ​ 459 ​ (7) ​ 1 ​ 47 ​ (22) ​ 318 ​ 4 ​ 15 ​ 26 ​ 3 ​ 2 ​ 68 ​ (34) ​ (28) Others ​ 101 ​ (17) ​ (14) ​ 5 ​ (40) ​ 67 ​ (22) ​ (18) ​ 27 ​ 18 ​ 19 ​ 2 ​ (53) ​ (49) Total Product Sales 24,629 ​ 15 ​ 18 ​ 10,061 ​ 17 ​ 7,051 ​ 16 ​ 26 ​ 5,134 ​ 21 ​ 19 ​ 2,383 ​ (6) ​ 3 15 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.

Q2 2024 Product Sales year-on-y

Q2 2024 Product Sales year-on-year analysis	6 Months Ended
	Jun. 30, 2024
Q2 2024 Product Sales year-on-year analysis
Q2 2024 Product Sales year-on-year analysis	Table 26: Q2 2024 - Product Sales year-on-year analysis (Unreviewed) 16 The Q2 2024 information in respect of the three months ended 30 June 2024 included in the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ World ​ US ​ Emerging Markets ​ Europe ​ Established RoW ​ $m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 4,976 ​ 14 ​ 18 ​ 2,302 ​ 17 ​ 1,098 ​ 11 ​ 22 ​ 1,015 ​ 24 ​ 24 ​ 561 ​ (9) ​ 2 Tagrisso 1,608 ​ 8 ​ 12 ​ 658 ​ 13 ​ 432 ​ 6 ​ 15 ​ 327 ​ 15 ​ 15 ​ 191 ​ (12) ​ (1) Imfinzi 1,147 ​ 13 ​ 18 ​ 620 ​ 15 ​ 117 ​ 16 ​ 39 ​ 227 ​ 33 ​ 33 ​ 183 ​ (9) ​ 3 Calquence ​ 790 ​ 21 ​ 22 ​ 554 ​ 14 ​ 36 ​ 51 ​ 72 ​ 167 ​ 42 ​ 43 ​ 33 ​ 20 ​ 23 Lynparza 744 ​ 4 ​ 7 ​ 319 ​ 3 ​ 153 ​ 8 ​ 18 ​ 206 ​ 10 ​ 11 ​ 66 ​ (15) ​ (6) Enhertu ​ 127 ​ 89 ​ 99 ​ - ​ - ​ 77 ​ 60 ​ 72 ​ 31 ​ n/m ​ n/m ​ 19 ​ n/m ​ n/m Zoladex ​ 273 ​ 17 ​ 25 ​ 5 ​ 29 ​ 201 ​ 17 ​ 28 ​ 42 ​ 23 ​ 21 ​ 25 ​ 6 ​ 17 Imjudo ​ 74 ​ 17 ​ 19 ​ 49 ​ 37 ​ 4 ​ n/m ​ n/m ​ 8 ​ 64 ​ 55 ​ 13 ​ (38) ​ (30) Truqap 92 ​ n/m ​ n/m ​ 91 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ 1 ​ n/m ​ n/m Orpathys ​ 12 ​ (7) ​ (3) ​ - ​ - ​ 12 ​ (7) ​ (3) ​ - ​ - ​ - ​ - ​ - ​ - Others 109 ​ (17) ​ (11) ​ 6 ​ 24 ​ 66 ​ (16) ​ (10) ​ 7 ​ (11) ​ (10) ​ 30 ​ (26) ​ (16) BioPharmaceuticals: CVRM 3,153 ​ 18 ​ 22 ​ 735 ​ 11 ​ 1,384 ​ 17 ​ 24 ​ 843 ​ 38 ​ 38 ​ 191 ​ (14) ​ (3) Farxiga ​ 1,940 ​ 29 ​ 32 ​ 394 ​ 16 ​ 763 ​ 32 ​ 39 ​ 680 ​ 49 ​ 49 ​ 103 ​ (23) ​ (14) Brilinta 342 ​ 3 ​ 5 ​ 191 ​ 7 ​ 78 ​ (1) ​ 6 ​ 69 ​ 1 ​ 1 ​ 4 ​ (38) ​ (23) Crestor ​ 292 ​ 4 ​ 11 ​ 12 ​ (2) ​ 234 ​ 8 ​ 14 ​ 10 ​ (34) ​ (32) ​ 36 ​ 3 ​ 15 Seloken / Toprol-XL 150 ​ (8) ​ - ​ - ​ n/m ​ 146 ​ (8) ​ - ​ 3 ​ 46 ​ 53 ​ 1 ​ (40) ​ (38) Lokelma 136 ​ 36 ​ 41 ​ 64 ​ 29 ​ 21 ​ 68 ​ 78 ​ 23 ​ 63 ​ 64 ​ 28 ​ 16 ​ 33 roxadustat 88 ​ 20 ​ 26 ​ - ​ - ​ 88 ​ 20 ​ 26 ​ - ​ - ​ - ​ - ​ - ​ - Andexxa ​ 59 ​ 29 ​ 35 ​ 22 ​ 34 ​ 1 ​ n/m ​ n/m ​ 22 ​ 51 ​ 51 ​ 14 ​ (6) ​ 8 Wainua ​ 16 ​ n/m ​ n/m ​ 16 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Others 130 ​ (26) ​ (24) ​ 36 ​ (45) ​ 53 ​ (19) ​ (14) ​ 36 ​ (9) ​ (8) ​ 5 ​ (14) ​ (12) BioPharmaceuticals: R&I 1,797 ​ 21 ​ 24 ​ 830 ​ 23 ​ 444 ​ 23 ​ 34 ​ 350 ​ 21 ​ 21 ​ 173 ​ 8 ​ 14 Symbicort 722 ​ 20 ​ 25 ​ 299 ​ 49 ​ 197 ​ 12 ​ 25 ​ 143 ​ 4 ​ 5 ​ 83 ​ (4) ​ (1) Fasenra 423 ​ 4 ​ 5 ​ 268 ​ - ​ 19 ​ 33 ​ 46 ​ 99 ​ 11 ​ 11 ​ 37 ​ 3 ​ 11 Pulmicort 155 ​ 25 ​ 30 ​ 3 ​ (53) ​ 126 ​ 40 ​ 47 ​ 17 ​ 6 ​ 2 ​ 9 ​ (18) ​ (13) Breztri ​ 235 ​ 44 ​ 47 ​ 120 ​ 43 ​ 61 ​ 42 ​ 49 ​ 35 ​ 68 ​ 69 ​ 19 ​ 26 ​ 37 Tezspire ​ 57 ​ n/m ​ n/m ​ - ​ - ​ 3 ​ n/m ​ n/m ​ 35 ​ n/m ​ n/m ​ 19 ​ n/m ​ n/m Saphnelo ​ 112 ​ 65 ​ 65 ​ 101 ​ 59 ​ 1 ​ 28 ​ n/m ​ 6 ​ n/m ​ n/m ​ 4 ​ 90 ​ 86 Airsupra 14 ​ n/m ​ n/m ​ 14 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Others 79 ​ (24) ​ (22) ​ 25 ​ (52) ​ 37 ​ 7 ​ 12 ​ 15 ​ 2 ​ 3 ​ 2 ​ (6) ​ (4) BioPharmaceuticals: V&I 112 ​ 28 ​ 42 ​ 28 ​ n/m ​ 41 ​ (10) ​ 4 ​ 7 ​ (55) ​ (53) ​ 36 ​ 36 ​ 55 Synagis ​ 81 ​ (6) ​ 8 ​ (1) ​ n/m ​ 41 ​ (16) ​ (2) ​ 6 ​ (42) ​ (42) ​ 35 ​ 27 ​ 46 Beyfortus ​ 28 ​ n/m ​ n/m ​ 27 ​ n/m ​ - ​ - ​ - ​ - ​ n/m ​ (91) ​ 1 ​ n/m ​ n/m FluMist ​ 2 ​ n/m ​ n/m ​ 2 ​ n/m ​ - ​ - ​ - ​ - ​ (26) ​ (21) ​ - ​ - ​ - COVID-19 mAbs ​ 1 ​ n/m ​ n/m ​ - ​ - ​ - ​ n/m ​ n/m ​ 1 ​ (65) ​ (64) ​ - ​ (99) ​ (99) Others ​ - ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ n/m ​ n/m ​ - ​ - ​ - Rare Disease 2,147 ​ 10 ​ 14 ​ 1,311 ​ 10 ​ 203 ​ 35 ​ 67 ​ 392 ​ 3 ​ 3 ​ 241 ​ 7 ​ 18 Ultomiris ​ 946 ​ 33 ​ 36 ​ 550 ​ 27 ​ 35 ​ n/m ​ n/m ​ 209 ​ 38 ​ 38 ​ 152 ​ 38 ​ 56 Soliris 700 ​ (14) ​ (8) ​ 398 ​ (11) ​ 129 ​ 30 ​ 74 ​ 118 ​ (36) ​ (36) ​ 55 ​ (36) ​ (33) Strensiq ​ 340 ​ 13 ​ 14 ​ 283 ​ 14 ​ 10 ​ 7 ​ 15 ​ 24 ​ 13 ​ 13 ​ 23 ​ 4 ​ 17 Koselugo 114 ​ 43 ​ 45 ​ 55 ​ 13 ​ 24 ​ 73 ​ 80 ​ 26 ​ n/m ​ n/m ​ 9 ​ 63 ​ 85 Kanuma ​ 47 ​ 3 ​ 8 ​ 25 ​ 21 ​ 5 ​ (54) ​ (49) ​ 15 ​ 28 ​ 33 ​ 2 ​ 11 ​ 41 Other medicines ​ 267 ​ (11) ​ (5) ​ 28 ​ (13) ​ 179 ​ (3) ​ 5 ​ 24 ​ (7) ​ (7) ​ 36 ​ (38) ​ (32) Nexium ​ 219 ​ (12) ​ (5) ​ 25 ​ (17) ​ 146 ​ (2) ​ 7 ​ 13 ​ (5) ​ (5) ​ 35 ​ (37) ​ (32) Others ​ 48 ​ (9) ​ (6) ​ 3 ​ 39 ​ 33 ​ (8) ​ (4) ​ 11 ​ (9) ​ (9) ​ 1 ​ (54) ​ (49) Total Product Sales 12,452 ​ 14 ​ 18 ​ 5,234 ​ 16 ​ 3,349 ​ 15 ​ 25 ​ 2,631 ​ 23 ​ 23 ​ 1,238 ​ (5) ​ 5 16 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.

Alliance Revenue

Alliance Revenue	6 Months Ended
	Jun. 30, 2024
Alliance revenue [Abstract]
Alliance revenue	Table 27: Alliance Revenue ​ ​ ​ ​ ​ ​ ​ H1 2024 H1 2023 ​ ​ $m $m Enhertu ​ 683 475 Tezspire ​ 180 105 Beyfortus ​ 26 - Other Alliance Revenue ​ 50 47 Total ​ 939 627 ​

Collaboration Revenue

Collaboration Revenue	6 Months Ended
	Jun. 30, 2024
Collaboration Revenue.
Collaboration Revenue	Table 28: Collaboration Revenue ​ ​ ​ ​ ​ ​ ​ H1 2024 H1 2023 ​ ​ $m $m Farxiga ​ 49 25 COVID-19 mAbs: licence fees ​ - 180 Other Collaboration Revenue ​ - 15 Total ​ 49 220 ​

Other operating income and expe

Other operating income and expense	6 Months Ended
	Jun. 30, 2024
Other operating income and expense
Other operating income and expense	Table 29: Other operating income and expense ​ ​ ​ ​ ​ H1 2024 H1 2023 ​ $m $m brazikumab licence termination funding - 75 Divestment of US rights to Pulmicort Flexhaler - 241 Update to the contractual relationships for Beyfortus (nirsevimab) - 712 Other 127 135 Total 127 1,163 ​

Basis of preparation and acco_2

Basis of preparation and accounting policies (Policies)	6 Months Ended
	Jun. 30, 2024
Basis of preparation and accounting policies
Basis of preparation and accounting policies	These unaudited condensed consolidated Interim financial statements for the six months ended 30 June 2024 have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards. The unaudited Interim financial statements for the six months ended 30 June 2024 were approved by the Board of Directors for publication on 25 July 2024. This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 31 December 2023 were prepared in accordance with UK-adopted international accounting standards and with the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRS Accounting Standards as issued by the IASB and International Accounting Standards as adopted by the European Union. Except for the estimation of the interim income tax charge, the Interim financial statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2023. The comparative figures for the financial year ended 31 December 2023 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the Registrar of Companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006.
Going concern	Going concern ​ The Group has considerable financial resources available. As at 30 June 2024, the Group has $11.8bn in financial resources (cash and cash equivalent balances of $6.9bn and undrawn committed bank facilities of $4.9bn, with $5.4bn of borrowings due within one year. These facilities contain no financial covenants and were undrawn at 30 June 2024. The $4.9bn facilities are available until April 2029. Additionally, there are a further $2.0bn undrawn committed bank facilities available until February 2025. ​ The Group’s revenues are largely derived from sales of medicines covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. Accordingly, they continue to adopt the going concern basis in preparing the Interim financial statements.
Legal proceedings	Legal proceedings ​ The information contained in Note 6 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and Form 20-F Information 202 3
Employee Benefit Trust	Employee Benefit Trust ​ Following an amendment to the Employee Benefit Trust (EBT) Deed on 10th June 2024, AstraZeneca obtained control and commenced consolidation of the EBT. Going forward, cash paid on purchases of AstraZeneca Ordinary shares or American Depository Receipts, will be presented within Financing activities in the Cash flow statement. ​

Net Debt (Tables)

Net Debt (Tables)	6 Months Ended
	Jun. 30, 2024
Net Debt.
Schedule of Net Debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At 1 Jan ​ Cash ​ ​ ​ Non-cash ​ Exchange ​ At 30 Jun ​ ​ 2024 ​ flow ​ Acquisitions ​ & other ​ movements ​ 2024 ​ $m $m $m ​ $m $m $m Non-current instalments of loans (22,365) ​ (4,973) ​ (3) ​ (2) ​ 118 ​ (27,225) Non-current instalments of leases ​ (857) ​ - ​ (12) ​ (97) ​ 17 ​ (949) Total long-term debt (23,222) ​ (4,973) ​ (15) ​ (99) ​ 135 ​ (28,174) Current instalments of loans (4,614) ​ 2,583 ​ (9) ​ (5) ​ 27 ​ (2,018) Current instalments of leases (271) ​ 174 ​ (6) ​ (197) ​ 8 ​ (292) Commercial paper ​ - ​ (2,453) ​ - ​ - ​ - ​ (2,453) Collateral received from derivative counterparties (215) ​ 13 ​ - ​ - ​ - ​ (202) Other short-term borrowings excluding overdrafts ​ (97) ​ (63) ​ - ​ - ​ 5 ​ (155) Overdrafts (203) ​ (35) ​ - ​ - ​ (1) ​ (239) Total current debt ​ (5,400) ​ 219 ​ (15) ​ (202) ​ 39 ​ (5,359) Gross borrowings ​ (28,622) ​ (4,754) ​ (30) ​ (301) ​ 174 ​ (33,533) Net derivative financial instruments ​ 150 ​ 65 ​ - ​ (82) ​ - ​ 133 Net borrowings ​ (28,472) ​ (4,689) ​ (30) ​ (383) ​ 174 ​ (33,400) Cash and cash equivalents ​ 5,840 ​ 885 ​ 242 ​ - ​ (51) ​ 6,916 Other investments - current ​ 122 ​ (42) ​ 87 ​ - ​ (7) ​ 160 Cash and investments ​ 5,962 ​ 843 ​ 329 ​ - ​ (58) ​ 7,076 Net debt ​ (22,510) ​ (3,846) ​ 299 ​ (383) ​ 116 ​ (26,324)

Financial instruments (Tables)

Financial instruments (Tables)	6 Months Ended
	Jun. 30, 2024
Financial instruments
Schedule of Contingent consideration	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2024 ​ 2023 ​ ​ Diabetes ​ ​ ​ ​ ​ ​ ​ alliance Other Total Total ​ ​ $m ​ $m ​ $m ​ $m At 1 January 1,945 ​ 192 ​ 2,137 ​ 2,222 Additions through business combinations ​ - ​ 198 ​ 198 ​ 60 Settlements (473) ​ (1) ​ (474) ​ (398) Revaluations ​ 220 ​ 31 ​ 251 ​ 202 Discount unwind 50 ​ 7 ​ 57 ​ 66 At 30 June 1,742 ​ 427 ​ 2,169 ​ 2,152

Business combinations (Tables)

Business combinations (Tables)	6 Months Ended
	Jun. 30, 2024
Gracell Biotechnologies Inc.
Disclosure of detailed information about business combination [line items]
Schedule of business combination	​ ​ ​ ​ ​ ​ ​ ​ ​ Fair values ​ ​ $m Intangible assets ​ 1,038 Cash and cash equivalents ​ 212 Net deferred tax liability ​ (260) Other immaterial balances ​ (89) Total net assets acquired ​ 901 Goodwill ​ 136 Consideration ​ 1,037
Fusion Pharmaceuticals Inc.
Disclosure of detailed information about business combination [line items]
Schedule of business combination	​ ​ ​ ​ ​ ​ ​ ​ ​ Fair values ​ ​ $m Intangible assets ​ 1,326 Cash and cash equivalents ​ 30 Current investments ​ 87 Net deferred tax liability ​ (246) Other immaterial balances ​ 51 Total net assets acquired ​ 1,248 Goodwill ​ 947 Consideration ​ 2,195

H1 2024 - Product Sales year-_2

H1 2024 - Product Sales year-on-year analysis (Tables)	6 Months Ended
	Jun. 30, 2024
H1 2024 - Product Sales year-on-year analysis
H1 2024 Product Sales year-on-year analysis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ World ​ US ​ Emerging Markets ​ Europe ​ Established RoW ​ $m Act % chg CER % chg ​ $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 9,737 ​ 17 ​ 21 ​ 4,387 ​ 20 ​ 2,300 ​ 18 ​ 28 ​ 1,967 ​ 25 ​ 23 ​ 1,083 ​ (2) ​ 8 Tagrisso 3,203 ​ 10 ​ 13 ​ 1,282 ​ 16 ​ 919 ​ 8 ​ 16 ​ 628 ​ 16 ​ 15 ​ 374 ​ (11) ​ (2) Imfinzi 2,259 ​ 20 ​ 25 ​ 1,202 ​ 17 ​ 245 ​ 35 ​ 58 ​ 459 ​ 38 ​ 36 ​ 353 ​ 7 ​ 19 Calquence ​ 1,508 ​ 27 ​ 28 ​ 1,048 ​ 21 ​ 75 ​ 82 ​ n/m ​ 320 ​ 42 ​ 41 ​ 65 ​ 30 ​ 34 Lynparza ​ 1,450 ​ 6 ​ 9 ​ 607 ​ 5 ​ 320 ​ 15 ​ 26 ​ 398 ​ 9 ​ 8 ​ 125 ​ (14) ​ (6) Enhertu ​ 249 ​ n/m ​ n/m ​ - ​ - ​ 161 ​ n/m ​ n/m ​ 57 ​ n/m ​ n/m ​ 31 ​ n/m ​ n/m Zoladex ​ 549 ​ 19 ​ 27 ​ 8 ​ 20 ​ 415 ​ 22 ​ 31 ​ 77 ​ 16 ​ 14 ​ 49 ​ 2 ​ 12 Imjudo ​ 136 ​ 35 ​ 38 ​ 88 ​ 30 ​ 7 ​ n/m ​ n/m ​ 16 ​ n/m ​ n/m ​ 25 ​ (5) ​ 6 Truqap ​ 142 ​ n/m ​ n/m ​ 141 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ 1 ​ n/m ​ n/m Orpathys ​ 25 ​ 14 ​ 19 ​ - ​ - ​ 25 ​ 14 ​ 19 ​ - ​ - ​ - ​ - ​ - ​ - Others 216 ​ (21) ​ (15) ​ 11 ​ 6 ​ 133 ​ (21) ​ (15) ​ 12 ​ (36) ​ (36) ​ 60 ​ (21) ​ (12) BioPharmaceuticals: CVRM 6,164 ​ 18 ​ 22 ​ 1,483 ​ 16 ​ 2,749 ​ 17 ​ 24 ​ 1,559 ​ 33 ​ 32 ​ 373 ​ (8) ​ 2 Farxiga ​ 3,785 ​ 35 ​ 38 ​ 867 ​ 37 ​ 1,474 ​ 37 ​ 44 ​ 1,233 ​ 45 ​ 44 ​ 211 ​ (15) ​ (5) Brilinta ​ 665 ​ - ​ 2 ​ 354 ​ (1) ​ 166 ​ 4 ​ 14 ​ 136 ​ - ​ (1) ​ 9 ​ (26) ​ (19) Crestor ​ 589 ​ 1 ​ 6 ​ 22 ​ (18) ​ 475 ​ 4 ​ 9 ​ 22 ​ (30) ​ (29) ​ 70 ​ 3 ​ 13 Seloken / Toprol-XL 315 ​ (8) ​ (1) ​ - ​ n/m ​ 307 ​ (8) ​ (1) ​ 6 ​ 4 ​ 7 ​ 2 ​ (39) ​ (37) Lokelma 249 ​ 26 ​ 30 ​ 115 ​ 10 ​ 42 ​ 75 ​ 83 ​ 41 ​ 62 ​ 61 ​ 51 ​ 16 ​ 31 roxadustat 163 ​ 22 ​ 27 ​ - ​ - ​ 163 ​ 22 ​ 27 ​ - ​ - ​ - ​ - ​ n/m ​ n/m Andexxa ​ 105 ​ 18 ​ 21 ​ 42 ​ 14 ​ 2 ​ n/m ​ n/m ​ 40 ​ 38 ​ 36 ​ 21 ​ (9) ​ 4 Wainua ​ 21 ​ n/m ​ n/m ​ 21 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Others 272 ​ (30) ​ (28) ​ 62 ​ (50) ​ 120 ​ (27) ​ (22) ​ 81 ​ (10) ​ (10) ​ 9 ​ (7) ​ (5) BioPharmaceuticals: R&I 3,601 ​ 17 ​ 20 ​ 1,567 ​ 21 ​ 1,032 ​ 16 ​ 23 ​ 680 ​ 17 ​ 16 ​ 322 ​ 7 ​ 12 Symbicort 1,491 ​ 16 ​ 19 ​ 598 ​ 38 ​ 450 ​ 11 ​ 21 ​ 286 ​ - ​ (1) ​ 157 ​ (4) ​ (2) Fasenra 781 ​ 5 ​ 6 ​ 478 ​ 2 ​ 41 ​ 45 ​ 53 ​ 192 ​ 9 ​ 8 ​ 70 ​ (2) ​ 6 Pulmicort ​ 379 ​ 10 ​ 14 ​ 8 ​ (53) ​ 317 ​ 16 ​ 22 ​ 37 ​ 1 ​ (1) ​ 17 ​ (13) ​ (9) Breztri ​ 454 ​ 48 ​ 51 ​ 225 ​ 37 ​ 131 ​ 61 ​ 69 ​ 65 ​ 80 ​ 79 ​ 33 ​ 33 ​ 44 Tezspire ​ 100 ​ n/m ​ n/m ​ - ​ - ​ 5 ​ n/m ​ n/m ​ 61 ​ n/m ​ n/m ​ 34 ​ n/m ​ n/m Saphnelo ​ 203 ​ 77 ​ 77 ​ 184 ​ 71 ​ 2 ​ n/m ​ n/m ​ 10 ​ n/m ​ n/m ​ 7 ​ 86 ​ 91 Airsupra 21 ​ n/m ​ n/m ​ 21 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Others 172 ​ (27) ​ (26) ​ 53 ​ (47) ​ 86 ​ (18) ​ (14) ​ 29 ​ 3 ​ 2 ​ 4 ​ (12) ​ (10) BioPharmaceuticals: V&I 324 ​ (27) ​ (24) ​ 55 ​ n/m ​ 131 ​ (12) ​ (7) ​ 81 ​ (28) ​ (30) ​ 57 ​ (68) ​ (65) Synagis ​ 253 ​ (11) ​ (6) ​ (1) ​ n/m ​ 131 ​ 4 ​ 10 ​ 67 ​ (27) ​ (29) ​ 56 ​ (15) ​ (6) Beyfortus ​ 54 ​ n/m ​ n/m ​ 53 ​ n/m ​ - ​ - ​ - ​ - ​ (81) ​ (61) ​ 1 ​ n/m ​ n/m FluMist ​ 8 ​ n/m ​ n/m ​ 3 ​ n/m ​ - ​ - ​ - ​ 5 ​ n/m ​ 97 ​ - ​ n/m ​ n/m COVID-19 mAbs ​ 3 ​ (98) ​ (98) ​ - ​ - ​ - ​ n/m ​ n/m ​ 3 ​ (58) ​ (59) ​ - ​ n/m ​ n/m Others ​ 6 ​ (79) ​ (80) ​ - ​ - ​ - ​ n/m ​ n/m ​ 6 ​ (41) ​ (43) ​ - ​ n/m ​ n/m Rare Disease 4,243 ​ 11 ​ 15 ​ 2,517 ​ 10 ​ 454 ​ 40 ​ 70 ​ 794 ​ 3 ​ 2 ​ 478 ​ 9 ​ 20 Ultomiris 1,804 ​ 32 ​ 35 ​ 1,032 ​ 27 ​ 66 ​ n/m ​ n/m ​ 411 ​ 32 ​ 31 ​ 295 ​ 42 ​ 58 Soliris ​ 1,439 ​ (13) ​ (8) ​ 808 ​ (9) ​ 255 ​ 19 ​ 54 ​ 260 ​ (29) ​ (30) ​ 116 ​ (33) ​ (30) Strensiq ​ 653 ​ 16 ​ 18 ​ 529 ​ 17 ​ 31 ​ 30 ​ 47 ​ 48 ​ 14 ​ 12 ​ 45 ​ 4 ​ 15 Koselugo 247 ​ 55 ​ 64 ​ 101 ​ 13 ​ 83 ​ n/m ​ n/m ​ 45 ​ 95 ​ 92 ​ 18 ​ n/m ​ n/m Kanuma ​ 100 ​ 17 ​ 20 ​ 47 ​ 18 ​ 19 ​ 7 ​ 20 ​ 30 ​ 24 ​ 25 ​ 4 ​ 11 ​ 20 Other medicines ​ 560 ​ (9) ​ (2) ​ 52 ​ (24) ​ 385 ​ (1) ​ 8 ​ 53 ​ 10 ​ 10 ​ 70 ​ (35) ​ (29) Nexium ​ 459 ​ (7) ​ 1 ​ 47 ​ (22) ​ 318 ​ 4 ​ 15 ​ 26 ​ 3 ​ 2 ​ 68 ​ (34) ​ (28) Others ​ 101 ​ (17) ​ (14) ​ 5 ​ (40) ​ 67 ​ (22) ​ (18) ​ 27 ​ 18 ​ 19 ​ 2 ​ (53) ​ (49) Total Product Sales 24,629 ​ 15 ​ 18 ​ 10,061 ​ 17 ​ 7,051 ​ 16 ​ 26 ​ 5,134 ​ 21 ​ 19 ​ 2,383 ​ (6) ​ 3 15 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.

Q4 2023 Product Sales year-on-y

Q4 2023 Product Sales year-on-year analysis (Tables)	6 Months Ended
	Jun. 30, 2024
Q2 2024 Product Sales year-on-year analysis
Q2 2024 Product Sales year-on-year analysis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ World ​ US ​ Emerging Markets ​ Europe ​ Established RoW ​ $m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 4,976 ​ 14 ​ 18 ​ 2,302 ​ 17 ​ 1,098 ​ 11 ​ 22 ​ 1,015 ​ 24 ​ 24 ​ 561 ​ (9) ​ 2 Tagrisso 1,608 ​ 8 ​ 12 ​ 658 ​ 13 ​ 432 ​ 6 ​ 15 ​ 327 ​ 15 ​ 15 ​ 191 ​ (12) ​ (1) Imfinzi 1,147 ​ 13 ​ 18 ​ 620 ​ 15 ​ 117 ​ 16 ​ 39 ​ 227 ​ 33 ​ 33 ​ 183 ​ (9) ​ 3 Calquence ​ 790 ​ 21 ​ 22 ​ 554 ​ 14 ​ 36 ​ 51 ​ 72 ​ 167 ​ 42 ​ 43 ​ 33 ​ 20 ​ 23 Lynparza 744 ​ 4 ​ 7 ​ 319 ​ 3 ​ 153 ​ 8 ​ 18 ​ 206 ​ 10 ​ 11 ​ 66 ​ (15) ​ (6) Enhertu ​ 127 ​ 89 ​ 99 ​ - ​ - ​ 77 ​ 60 ​ 72 ​ 31 ​ n/m ​ n/m ​ 19 ​ n/m ​ n/m Zoladex ​ 273 ​ 17 ​ 25 ​ 5 ​ 29 ​ 201 ​ 17 ​ 28 ​ 42 ​ 23 ​ 21 ​ 25 ​ 6 ​ 17 Imjudo ​ 74 ​ 17 ​ 19 ​ 49 ​ 37 ​ 4 ​ n/m ​ n/m ​ 8 ​ 64 ​ 55 ​ 13 ​ (38) ​ (30) Truqap 92 ​ n/m ​ n/m ​ 91 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ 1 ​ n/m ​ n/m Orpathys ​ 12 ​ (7) ​ (3) ​ - ​ - ​ 12 ​ (7) ​ (3) ​ - ​ - ​ - ​ - ​ - ​ - Others 109 ​ (17) ​ (11) ​ 6 ​ 24 ​ 66 ​ (16) ​ (10) ​ 7 ​ (11) ​ (10) ​ 30 ​ (26) ​ (16) BioPharmaceuticals: CVRM 3,153 ​ 18 ​ 22 ​ 735 ​ 11 ​ 1,384 ​ 17 ​ 24 ​ 843 ​ 38 ​ 38 ​ 191 ​ (14) ​ (3) Farxiga ​ 1,940 ​ 29 ​ 32 ​ 394 ​ 16 ​ 763 ​ 32 ​ 39 ​ 680 ​ 49 ​ 49 ​ 103 ​ (23) ​ (14) Brilinta 342 ​ 3 ​ 5 ​ 191 ​ 7 ​ 78 ​ (1) ​ 6 ​ 69 ​ 1 ​ 1 ​ 4 ​ (38) ​ (23) Crestor ​ 292 ​ 4 ​ 11 ​ 12 ​ (2) ​ 234 ​ 8 ​ 14 ​ 10 ​ (34) ​ (32) ​ 36 ​ 3 ​ 15 Seloken / Toprol-XL 150 ​ (8) ​ - ​ - ​ n/m ​ 146 ​ (8) ​ - ​ 3 ​ 46 ​ 53 ​ 1 ​ (40) ​ (38) Lokelma 136 ​ 36 ​ 41 ​ 64 ​ 29 ​ 21 ​ 68 ​ 78 ​ 23 ​ 63 ​ 64 ​ 28 ​ 16 ​ 33 roxadustat 88 ​ 20 ​ 26 ​ - ​ - ​ 88 ​ 20 ​ 26 ​ - ​ - ​ - ​ - ​ - ​ - Andexxa ​ 59 ​ 29 ​ 35 ​ 22 ​ 34 ​ 1 ​ n/m ​ n/m ​ 22 ​ 51 ​ 51 ​ 14 ​ (6) ​ 8 Wainua ​ 16 ​ n/m ​ n/m ​ 16 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Others 130 ​ (26) ​ (24) ​ 36 ​ (45) ​ 53 ​ (19) ​ (14) ​ 36 ​ (9) ​ (8) ​ 5 ​ (14) ​ (12) BioPharmaceuticals: R&I 1,797 ​ 21 ​ 24 ​ 830 ​ 23 ​ 444 ​ 23 ​ 34 ​ 350 ​ 21 ​ 21 ​ 173 ​ 8 ​ 14 Symbicort 722 ​ 20 ​ 25 ​ 299 ​ 49 ​ 197 ​ 12 ​ 25 ​ 143 ​ 4 ​ 5 ​ 83 ​ (4) ​ (1) Fasenra 423 ​ 4 ​ 5 ​ 268 ​ - ​ 19 ​ 33 ​ 46 ​ 99 ​ 11 ​ 11 ​ 37 ​ 3 ​ 11 Pulmicort 155 ​ 25 ​ 30 ​ 3 ​ (53) ​ 126 ​ 40 ​ 47 ​ 17 ​ 6 ​ 2 ​ 9 ​ (18) ​ (13) Breztri ​ 235 ​ 44 ​ 47 ​ 120 ​ 43 ​ 61 ​ 42 ​ 49 ​ 35 ​ 68 ​ 69 ​ 19 ​ 26 ​ 37 Tezspire ​ 57 ​ n/m ​ n/m ​ - ​ - ​ 3 ​ n/m ​ n/m ​ 35 ​ n/m ​ n/m ​ 19 ​ n/m ​ n/m Saphnelo ​ 112 ​ 65 ​ 65 ​ 101 ​ 59 ​ 1 ​ 28 ​ n/m ​ 6 ​ n/m ​ n/m ​ 4 ​ 90 ​ 86 Airsupra 14 ​ n/m ​ n/m ​ 14 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Others 79 ​ (24) ​ (22) ​ 25 ​ (52) ​ 37 ​ 7 ​ 12 ​ 15 ​ 2 ​ 3 ​ 2 ​ (6) ​ (4) BioPharmaceuticals: V&I 112 ​ 28 ​ 42 ​ 28 ​ n/m ​ 41 ​ (10) ​ 4 ​ 7 ​ (55) ​ (53) ​ 36 ​ 36 ​ 55 Synagis ​ 81 ​ (6) ​ 8 ​ (1) ​ n/m ​ 41 ​ (16) ​ (2) ​ 6 ​ (42) ​ (42) ​ 35 ​ 27 ​ 46 Beyfortus ​ 28 ​ n/m ​ n/m ​ 27 ​ n/m ​ - ​ - ​ - ​ - ​ n/m ​ (91) ​ 1 ​ n/m ​ n/m FluMist ​ 2 ​ n/m ​ n/m ​ 2 ​ n/m ​ - ​ - ​ - ​ - ​ (26) ​ (21) ​ - ​ - ​ - COVID-19 mAbs ​ 1 ​ n/m ​ n/m ​ - ​ - ​ - ​ n/m ​ n/m ​ 1 ​ (65) ​ (64) ​ - ​ (99) ​ (99) Others ​ - ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ n/m ​ n/m ​ - ​ - ​ - Rare Disease 2,147 ​ 10 ​ 14 ​ 1,311 ​ 10 ​ 203 ​ 35 ​ 67 ​ 392 ​ 3 ​ 3 ​ 241 ​ 7 ​ 18 Ultomiris ​ 946 ​ 33 ​ 36 ​ 550 ​ 27 ​ 35 ​ n/m ​ n/m ​ 209 ​ 38 ​ 38 ​ 152 ​ 38 ​ 56 Soliris 700 ​ (14) ​ (8) ​ 398 ​ (11) ​ 129 ​ 30 ​ 74 ​ 118 ​ (36) ​ (36) ​ 55 ​ (36) ​ (33) Strensiq ​ 340 ​ 13 ​ 14 ​ 283 ​ 14 ​ 10 ​ 7 ​ 15 ​ 24 ​ 13 ​ 13 ​ 23 ​ 4 ​ 17 Koselugo 114 ​ 43 ​ 45 ​ 55 ​ 13 ​ 24 ​ 73 ​ 80 ​ 26 ​ n/m ​ n/m ​ 9 ​ 63 ​ 85 Kanuma ​ 47 ​ 3 ​ 8 ​ 25 ​ 21 ​ 5 ​ (54) ​ (49) ​ 15 ​ 28 ​ 33 ​ 2 ​ 11 ​ 41 Other medicines ​ 267 ​ (11) ​ (5) ​ 28 ​ (13) ​ 179 ​ (3) ​ 5 ​ 24 ​ (7) ​ (7) ​ 36 ​ (38) ​ (32) Nexium ​ 219 ​ (12) ​ (5) ​ 25 ​ (17) ​ 146 ​ (2) ​ 7 ​ 13 ​ (5) ​ (5) ​ 35 ​ (37) ​ (32) Others ​ 48 ​ (9) ​ (6) ​ 3 ​ 39 ​ 33 ​ (8) ​ (4) ​ 11 ​ (9) ​ (9) ​ 1 ​ (54) ​ (49) Total Product Sales 12,452 ​ 14 ​ 18 ​ 5,234 ​ 16 ​ 3,349 ​ 15 ​ 25 ​ 2,631 ​ 23 ​ 23 ​ 1,238 ​ (5) ​ 5 16 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.

Alliance Revenue (Tables)

Alliance Revenue (Tables)	6 Months Ended
	Jun. 30, 2024
Alliance revenue [Abstract]
Schedule of alliance revenue	​ ​ ​ ​ ​ ​ ​ H1 2024 H1 2023 ​ ​ $m $m Enhertu ​ 683 475 Tezspire ​ 180 105 Beyfortus ​ 26 - Other Alliance Revenue ​ 50 47 Total ​ 939 627 ​

Collaboration Revenue (Tables)

Collaboration Revenue (Tables)	6 Months Ended
	Jun. 30, 2024
Collaboration Revenue.
Schedule of collaboration revenue	​ ​ ​ ​ ​ ​ ​ H1 2024 H1 2023 ​ ​ $m $m Farxiga ​ 49 25 COVID-19 mAbs: licence fees ​ - 180 Other Collaboration Revenue ​ - 15 Total ​ 49 220 ​

Other operating income and ex_2

Other operating income and expense (Tables)	6 Months Ended
	Jun. 30, 2024
Other operating income and expense
Schedule of other operating income and expense	​ ​ ​ ​ ​ H1 2024 H1 2023 ​ $m $m brazikumab licence termination funding - 75 Divestment of US rights to Pulmicort Flexhaler - 241 Update to the contractual relationships for Beyfortus (nirsevimab) - 712 Other 127 135 Total 127 1,163 ​

Basis of preparation and acco_3

Basis of preparation and accounting policies (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2024		Jun. 30, 2023	Jun. 30, 2024		Jun. 30, 2023	Dec. 31, 2023
Disclosure of detailed information about borrowings [line items]
Alliance revenue	$ 482	[1]	$ 341	$ 939		$ 627
Borrowings	33,533			33,533			$ 28,622
Going concern
Financial resources	11,800			11,800
Cash and cash equivalents	6,916	[2]	$ 5,664	6,916	[2]	$ 5,664	$ 5,840
February 2025
Going concern
Undrawn committed bank facilities	2,000			2,000
April 2029
Going concern
Undrawn committed bank facilities	4,900			4,900
Due within one year
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 5,400			$ 5,400
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 30 June 2024 and 30 June 2023 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2023 has been audited by PricewaterhouseCoopers LLP.

Intangible assets - Net impairm

Intangible assets - Net impairment charges (reversals) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Feb. 19, 2024
Impairment of intangible assets
Payment for intangible assets	$ 1,474	$ 1,436
Icosavax, Inc
Impairment of intangible assets
Acquisition date fair value of consideration transferred, asset acquisition			$ 841
Intangible assets acquired			639
Cash and cash equivalents acquired			141
Marketable securities acquired			51
Contingent consideration liabilities recognised in asset acquisition			$ 300
Intangible assets other than goodwill
Impairment of intangible assets
Impairment loss (reversal of impairment loss)	$ 26	320
ALXN1840
Impairment of intangible assets
Impairment loss (reversal of impairment loss)		$ 244

Net Debt (Details)

Net Debt (Details) - USD ($) $ in Millions		6 Months Ended
		Jun. 30, 2024	Dec. 31, 2023
Interest bearing loans and borrowings
Non-current installments of loans at beginning of period		$ (22,365)
Non-current instalments of loans - Cash Flow		(4,973)
Non-current instalments of loans - Acquisitions		(3)
Non-current installments of loans - Non-cash & Other		(2)
Non-current installments of loans - Exchange Movements		118
Non-current installments of loans at end of period	[1]	(27,225)
Non-current installments of leases at beginning of period		(857)
Non-current instalments of leases - Acquisitions		(12)
Non-current installments of leases - Non-cash & Other		(97)
Non-current installments of leases - Exchange Movements		17
Non-current installments of leases at end of period	[1]	(949)
Total long-term debt at beginning of period		(23,222)
Total long-term debt - Cash Flow		(4,973)
Total long-term debt - Non-cash & Other		(99)
Total long-term debt - Acquisitions		(15)
Total long-term debt - Exchange Movements		135
Total long-term debt at end of period		(28,174)
Current instalments of loans at beginning of period		(4,614)
Current instalments of loans - Cash Flow		2,583
Current instalments of loans - Acquisitions		(9)
Current instalments of loans - Non-cash & Other		(5)
Current instalments of loans - Exchange Movements		27
Current instalments of loans at end of period		(2,018)
Current instalments of leases at beginning of period		(271)
Current instalments of leases - Cash Flow		174
Current instalments of leases - Acquisitions		(6)
Current instalments of leases - Non-cash & Other		(197)
Current instalments of leases - Exchange Movements		8
Current instalments of leases at end of period	[1]	(292)
Interest-bearing loans and borrowings at beginning of period		(5,129)
Interest-bearing loans and borrowings at end of period	[1]	(5,067)
Total current debt at beginning of period		(5,400)
Total current debt - Cash Flow		219
Total current debt - Acquisitions		(15)
Total current debt - Non-cash & Other		(202)
Total current debt - Exchange Movements		39
Total current debt at end of period		(5,359)
Gross borrowings at beginning of period		(28,622)
Gross borrowings - Cash Flow		(4,754)
Gross borrowings - Acquisitions		(30)
Gross borrowings - Non-cash & Other		(301)
Gross borrowings - Exchange Movements		174
Gross borrowings at end of period		(33,533)
Net derivative financial instruments at beginning of period		150
Net derivative financial instruments - Cash Flow		65
Net derivative financial instruments - Non-cash & Other		(82)
Net derivative financial instruments at end of period		133
Net borrowings at beginning of period		(28,472)
Net borrowings - Cash Flow		(4,689)
Net borrowings - Acquisitions		(30)
Net borrowings - Non-cash & Other		(383)
Net borrowings - Exchange Movements		174
Net borrowings at end of period		(33,400)
Cash and cash equivalents at the beginning of the period		5,840
Cash and cash equivalents - Cash Flow		885
Cash and cash equivalents - Acquisitions		242
Cash and cash equivalents - Exchange Movements		(51)
Cash and cash equivalents at the end of the period	[1]	6,916
Other investments - current at beginning of period		122
Other investments, current - Cash Flow		(42)
Other investments - current - Acquisitions		87
Other investments, current - Exchange Movements		(7)
Other investments - current at end of period	[1]	160
Cash and investments at beginning of period		5,962
Cash and investments - Cash Flow		843
Cash and investments - Acquisitions		329
Cash and investments - Exchange Movements		(58)
Cash and investments at end of period		7,076
Net debt at beginning of period		(22,510)
Net debt - Cash Flow		(3,846)
Net debt - Acquisitions		299
Net debt - Non-cash & Other		(383)
Net debt - Exchange Movements		116
Net debt at end of period		(26,324)
Cash collateral on financial derivatives		202	$ 215
Cash collateral posted by the Group		97	102
Increase (decrease) in net debt		3,814
Acerta Pharma
Interest bearing loans and borrowings
Share purchase liability		0	$ 833
Commercial paper
Interest bearing loans and borrowings
Current borrowings and current portion of non-current borrowing - Cash Flow		(2,453)
Interest-bearing loans and borrowings at end of period		(2,453)
Collateral received from derivative counterparties
Interest bearing loans and borrowings
Interest-bearing loans and borrowings at beginning of period		(215)
Current borrowings and current portion of non-current borrowing - Cash Flow		13
Interest-bearing loans and borrowings at end of period		(202)
Other Short-term borrowings excluding overdrafts
Interest bearing loans and borrowings
Interest-bearing loans and borrowings at beginning of period		(97)
Current borrowings and current portion of non-current borrowing - Cash Flow		(63)
Current borrowings and current portion of non-current borrowing - Exchange Movements		5
Interest-bearing loans and borrowings at end of period		(155)
Overdrafts
Interest bearing loans and borrowings
Interest-bearing loans and borrowings at beginning of period		(203)
Current borrowings and current portion of non-current borrowing - Cash Flow		(35)
Current borrowings and current portion of non-current borrowing - Exchange Movements		(1)
Interest-bearing loans and borrowings at end of period		$ (239)
[1] The Condensed consolidated statement of financial position as at 30 June 2024 and 30 June 2023 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2023 has been audited by PricewaterhouseCoopers LLP.

Net Debt - Narrative disclosure

Net Debt - Narrative disclosures (Details) $ in Millions	1 Months Ended	3 Months Ended	6 Months Ended
	Feb. 29, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Disclosure of detailed information about borrowings [line items]
Number of bonds repaid		2
Repayment of bonds		$ 2,569
Repayment of loans and borrowings		2,643	$ 2,643	$ 3,408
Fixed-rate notes maturing February 2027
Disclosure of detailed information about borrowings [line items]
Issue of fixed-rate notes	$ 1,250
Borrowings, interest rate	4.80%
Fixed-rate notes maturing February 2029
Disclosure of detailed information about borrowings [line items]
Issue of fixed-rate notes	$ 1,250
Borrowings, interest rate	4.85%
Fixed-rate notes maturing February 2031
Disclosure of detailed information about borrowings [line items]
Issue of fixed-rate notes	$ 1,000
Borrowings, interest rate	4.90%
Fixed-rate notes maturing February 2034
Disclosure of detailed information about borrowings [line items]
Issue of fixed-rate notes	$ 1,500
Borrowings, interest rate	5%
Commercial paper issued in 2024
Disclosure of detailed information about borrowings [line items]
Commercial papers, value		$ 2,453	$ 2,453	$ 0

Financial instruments (Details)

Financial instruments (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2024		Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Financial instruments fair value gains
Net gains/(losses) on equity investments measured at fair value through other comprehensive income	$ 54	[1]	$ (94)	$ 89	$ (48)
Non-cash and other movements				(550)	(594)
Net cash inflow from operating activities				5,571	4,851
Reconciliation of changes in contingent liabilities in business combination
Contingent liabilities recognised in business combination at beginning of period				2,137	2,222
Additions				198	60
Settlements				(474)	(398)
Revaluations				251	202
Discount unwind				57	66
Contingent liabilities recognised in business combination at end of period	2,169		$ 2,152	2,169	2,152
Diabetes alliance
Reconciliation of changes in contingent liabilities in business combination
Contingent liabilities recognised in business combination at beginning of period				1,945
Settlements				(473)
Revaluations				220
Discount unwind				50
Contingent liabilities recognised in business combination at end of period	1,742			1,742
Increase/decrease in contingent consideration balance with change in current estimates	$ 174			174
Percentage of reasonably possible increase or decrease in sales estimates	10%
Other
Reconciliation of changes in contingent liabilities in business combination
Contingent liabilities recognised in business combination at beginning of period				192
Additions				198
Settlements				(1)
Revaluations				31
Discount unwind				7
Contingent liabilities recognised in business combination at end of period	$ 427			427
Interest-Bearing Loans and Borrowings | Not measured at fair value in statement of financial position but for which fair value is disclosed
Financial instruments fair value gains
Carrying value, financial liabilities	33,533			33,533
Financial liabilities, at fair value	32,231			32,231
Financial assets at amortised cost
Financial instruments fair value gains
Cash collateral pledged to counterparties	97			97
Other Investments | Financial assets measured at fair value
Financial instruments fair value gains
Financial assets.	1,670			1,670
Money market funds | Financial assets measured at fair value
Financial instruments fair value gains
Financial assets.	5,463			5,463
Derivatives | Financial assets measured at fair value
Financial instruments fair value gains
Financial assets.	133			133
Level 3
Financial instruments fair value gains
Net gains/(losses) on equity investments measured at fair value through other comprehensive income				1	$ 1
Level 3 | Equity investments
Financial instruments fair value gains
Financial assets.	337			337		$ 313
Level 3 | Equity investments | Financial assets measured at fair value
Financial instruments fair value gains
Financial assets.	$ 350			$ 350
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP.

Business combinations - Gracell

Business combinations - Gracell (Details) - Gracell Biotechnologies Inc. $ in Millions	Feb. 22, 2024 USD ($)
Disclosure of detailed information about business combination [line items]
Contingent consideration	$ 54
Cash transferred	983
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]
Intangible assets	1,038
Cash and cash equivalents	212
Net deferred tax liability	(260)
Other immaterial balances	(89)
Total net assets acquired	901
Goodwill	136
Consideration	$ 1,037

Business Combinations - Fusion

Business Combinations - Fusion (Details) - Fusion Pharmaceuticals Inc. $ in Millions	Jun. 04, 2024 USD ($)
Disclosure of detailed information about business combination [line items]
Cash transferred	$ 2,051
Contingent consideration	$ 144
Percentage of ownership interest in acquiree held immediately prior to business combination	1%
Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date	$ 24
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]
Intangible assets	1,326
Cash and cash equivalents	30
Current investments	87
Net deferred tax liability	(246)
Other immaterial balances	51
Total net assets acquired	1,248
Goodwill	947
Consideration	2,195
FPI-2265 programme
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]
Intangible assets	848
FPI-2059 programme
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]
Intangible assets	165
AZD2068 programme
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]
Intangible assets	$ 313

Legal proceedings and conting_2

Legal proceedings and contingent liabilities - Legal proceedings (Details) $ in Thousands

1 Months Ended

2 Months Ended

6 Months Ended

12 Months Ended

36 Months Ended

May 31, 2024 USD ($)

Dec. 31, 2023 USD ($)

Dec. 31, 2022 employee

Jul. 31, 2020 USD ($)

Aug. 31, 2017 lawsuit

Jun. 30, 2024

Dec. 31, 2021 lawsuit

Dec. 31, 2019 lawsuit

Dec. 31, 2021 lawsuit

Jan. 31, 2024 patent

Oct. 31, 2023 USD ($)

Apr. 30, 2022 USD ($)

Oct. 31, 2012 agreement patent

Soliris patent proceedings

Commitments and contingent liabilities

Number of patents involved in patent proceedings | patent

6

Number of patents involved in proceedings that are subject to inter partes review | patent

5

PARP Inhibitor Royalty Dispute

Commitments and contingent liabilities

Number of disputed royalty-bearing patent license agreements | agreement

2

Calquence US Patent proceedings

Commitments and contingent liabilities

Number of generic manufacturers which settlement agreements have been entered with

5

Number of generic manufacturers with which proceedings are ongoing

3

Lokelma US patent proceedings

Commitments and contingent liabilities

Number of generic manufacturers which settlement agreements have been entered with

2

Nexium and LosecPrilosec US proceedings

Commitments and contingent liabilities

Legal proceedings provision

$ 425,000

Nexium and LosecPrilosec Canada proceedings

Commitments and contingent liabilities

Number of class action lawsuits brought against entity | lawsuit

3

Number of class action lawsuits dismissed | lawsuit

1

1

2

Commencement of major litigation | Soliris patent proceedings

Commitments and contingent liabilities

Number of patents involved in patent proceedings | patent

6

Number of patents involved in proceedings that are subject to inter partes review | patent

5

Daiichi Sankyo | Enhertu US patent proceedings

Commitments and contingent liabilities

Damages payable

$ 41,820

Royalties payable on sales, percent

8%

PARP Inhibitor Royalty Dispute

Commitments and contingent liabilities

Number of disputed royalty-bearing patent license agreements | patent

2

Pay Equity Litigation

Commitments and contingent liabilities

Number of plaintiffs in case

3

Tagrisso US patent proceedings

Commitments and contingent liabilities

Litigation settlement, amount awarded to counterparty

$ 107,500

Turkish Ministry of Health matter | Alexion Turkey

Commitments and contingent liabilities

Amount of civil settlements disclosed in case

$ 21,500

Definiens commercial litigation

Commitments and contingent liabilities

Amount of claims against entity

$ 140,000

Litigation settlement, amount awarded to counterparty

$ 46,430

US employment litigation

Commitments and contingent liabilities

Number of former employees that filed lawsuit for disparate treatment | employee

7

Subsequent Events (Details)

Subsequent Events (Details) - Major business combination - Amolyt Pharma $ in Millions	Jul. 15, 2024 USD ($)
Subsequent events
Total fair value of consideration	$ 1,050
Upfront payment	800
Contingent consideration	$ 250

H1 2024 - Product Sales year-_3

H1 2024 - Product Sales year-on-year analysis (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2024		Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Product sales
Product Sales	$ 12,452	[1]	$ 10,882	$ 24,629	$ 21,448
Actual %, year-on-year	14%			15%
CER %, year-on-year	18%			18%
US
Product sales
Product Sales	$ 5,234			$ 10,061
Actual %, year-on-year	16%			17%
Emerging Markets
Product sales
Product Sales	$ 3,349			$ 7,051
Actual %, year-on-year	15%			16%
CER %, year-on-year	25%			26%
Europe
Product sales
Product Sales	$ 2,631			$ 5,134
Actual %, year-on-year	23%			21%
CER %, year-on-year	23%			19%
Established ROW
Product sales
Product Sales	$ 1,238			$ 2,383
Actual %, year-on-year	(5.00%)			(6.00%)
CER %, year-on-year	5%			3%
Total Oncology
Product sales
Product Sales	$ 4,976			$ 9,737
Actual %, year-on-year	14%			17%
CER %, year-on-year	18%			21%
Total Oncology | US
Product sales
Product Sales	$ 2,302			$ 4,387
Actual %, year-on-year	17%			20%
Total Oncology | Emerging Markets
Product sales
Product Sales	$ 1,098			$ 2,300
Actual %, year-on-year	11%			18%
CER %, year-on-year	22%			28%
Total Oncology | Europe
Product sales
Product Sales	$ 1,015			$ 1,967
Actual %, year-on-year	24%			25%
CER %, year-on-year	24%			23%
Total Oncology | Established ROW
Product sales
Product Sales	$ 561			$ 1,083
Actual %, year-on-year	(9.00%)			(2.00%)
CER %, year-on-year	2%			8%
Tagrisso
Product sales
Product Sales	$ 1,608			$ 3,203
Actual %, year-on-year	8%			10%
CER %, year-on-year	12%			13%
Tagrisso | US
Product sales
Product Sales	$ 658			$ 1,282
Actual %, year-on-year	13%			16%
Tagrisso | Emerging Markets
Product sales
Product Sales	$ 432			$ 919
Actual %, year-on-year	6%			8%
CER %, year-on-year	15%			16%
Tagrisso | Europe
Product sales
Product Sales	$ 327			$ 628
Actual %, year-on-year	15%			16%
CER %, year-on-year	15%			15%
Tagrisso | Established ROW
Product sales
Product Sales	$ 191			$ 374
Actual %, year-on-year	(12.00%)			(11.00%)
CER %, year-on-year	(1.00%)			(2.00%)
Imfinzi
Product sales
Product Sales	$ 1,147			$ 2,259
Actual %, year-on-year	13%			20%
CER %, year-on-year	18%			25%
Imfinzi | US
Product sales
Product Sales	$ 620			$ 1,202
Actual %, year-on-year	15%			17%
Imfinzi | Emerging Markets
Product sales
Product Sales	$ 117			$ 245
Actual %, year-on-year	16%			35%
CER %, year-on-year	39%			58%
Imfinzi | Europe
Product sales
Product Sales	$ 227			$ 459
Actual %, year-on-year	33%			38%
CER %, year-on-year	33%			36%
Imfinzi | Established ROW
Product sales
Product Sales	$ 183			$ 353
Actual %, year-on-year	(9.00%)			7%
CER %, year-on-year	3%			19%
Calquence
Product sales
Product Sales	$ 790			$ 1,508
Actual %, year-on-year	21%			27%
CER %, year-on-year	22%			28%
Calquence | US
Product sales
Product Sales	$ 554			$ 1,048
Actual %, year-on-year	14%			21%
Calquence | Emerging Markets
Product sales
Product Sales	$ 36			$ 75
Actual %, year-on-year	51%			82%
CER %, year-on-year	72%
Calquence | Europe
Product sales
Product Sales	$ 167			$ 320
Actual %, year-on-year	42%			42%
CER %, year-on-year	43%			41%
Calquence | Established ROW
Product sales
Product Sales	$ 33			$ 65
Actual %, year-on-year	20%			30%
CER %, year-on-year	23%			34%
Lynparza
Product sales
Product Sales	$ 744			$ 1,450
Actual %, year-on-year	4%			6%
CER %, year-on-year	7%			9%
Lynparza | US
Product sales
Product Sales	$ 319			$ 607
Actual %, year-on-year	3%			5%
Lynparza | Emerging Markets
Product sales
Product Sales	$ 153			$ 320
Actual %, year-on-year	8%			15%
CER %, year-on-year	18%			26%
Lynparza | Europe
Product sales
Product Sales	$ 206			$ 398
Actual %, year-on-year	10%			9%
CER %, year-on-year	11%			8%
Lynparza | Established ROW
Product sales
Product Sales	$ 66			$ 125
Actual %, year-on-year	(15.00%)			(14.00%)
CER %, year-on-year	(6.00%)			(6.00%)
Enhertu
Product sales
Product Sales	$ 127			$ 249
Actual %, year-on-year	89%
CER %, year-on-year	99%
Enhertu | Emerging Markets
Product sales
Product Sales	$ 77			161
Actual %, year-on-year	60%
CER %, year-on-year	72%
Enhertu | Europe
Product sales
Product Sales	$ 31			57
Enhertu | Established ROW
Product sales
Product Sales	19			31
Zoladex
Product sales
Product Sales	$ 273			$ 549
Actual %, year-on-year	17%			19%
CER %, year-on-year	25%			27%
Zoladex | US
Product sales
Product Sales	$ 5			$ 8
Actual %, year-on-year	29%			20%
Zoladex | Emerging Markets
Product sales
Product Sales	$ 201			$ 415
Actual %, year-on-year	17%			22%
CER %, year-on-year	28%			31%
Zoladex | Europe
Product sales
Product Sales	$ 42			$ 77
Actual %, year-on-year	23%			16%
CER %, year-on-year	21%			14%
Zoladex | Established ROW
Product sales
Product Sales	$ 25			$ 49
Actual %, year-on-year	6%			2%
CER %, year-on-year	17%			12%
Imjudo
Product sales
Product Sales	$ 74			$ 136
Actual %, year-on-year	17%			35%
CER %, year-on-year	19%			38%
Imjudo | US
Product sales
Product Sales	$ 49			$ 88
Actual %, year-on-year	37%			30%
Imjudo | Emerging Markets
Product sales
Product Sales	$ 4			$ 7
Imjudo | Europe
Product sales
Product Sales	$ 8			16
Actual %, year-on-year	64%
CER %, year-on-year	55%
Imjudo | Established ROW
Product sales
Product Sales	$ 13			$ 25
Actual %, year-on-year	(38.00%)			(5.00%)
CER %, year-on-year	(30.00%)			6%
Truqap
Product sales
Product Sales	$ 92			$ 142
Truqap | US
Product sales
Product Sales	91			141
Truqap | Established ROW
Product sales
Product Sales	1			1
Orpathys
Product sales
Product Sales	$ 12			$ 25
Actual %, year-on-year	(7.00%)			14%
CER %, year-on-year	(3.00%)			19%
Orpathys | Emerging Markets
Product sales
Product Sales	$ 12			$ 25
Actual %, year-on-year	(7.00%)			14%
CER %, year-on-year	(3.00%)			19%
Oncology, Others
Product sales
Product Sales	$ 109			$ 216
Actual %, year-on-year	(17.00%)			(21.00%)
CER %, year-on-year	(11.00%)			(15.00%)
Oncology, Others | US
Product sales
Product Sales	$ 6			$ 11
Actual %, year-on-year	24%			6%
Oncology, Others | Emerging Markets
Product sales
Product Sales	$ 66			$ 133
Actual %, year-on-year	(16.00%)			(21.00%)
CER %, year-on-year	(10.00%)			(15.00%)
Oncology, Others | Europe
Product sales
Product Sales	$ 7			$ 12
Actual %, year-on-year	(11.00%)			(36.00%)
CER %, year-on-year	(10.00%)			(36.00%)
Oncology, Others | Established ROW
Product sales
Product Sales	$ 30			$ 60
Actual %, year-on-year	(26.00%)			(21.00%)
CER %, year-on-year	(16.00%)			(12.00%)
BioPharmaceuticals: total CVRM
Product sales
Product Sales	$ 3,153			$ 6,164
Actual %, year-on-year	18%			18%
CER %, year-on-year	22%			22%
BioPharmaceuticals: total CVRM | US
Product sales
Product Sales	$ 735			$ 1,483
Actual %, year-on-year	11%			16%
BioPharmaceuticals: total CVRM | Emerging Markets
Product sales
Product Sales	$ 1,384			$ 2,749
Actual %, year-on-year	17%			17%
CER %, year-on-year	24%			24%
BioPharmaceuticals: total CVRM | Europe
Product sales
Product Sales	$ 843			$ 1,559
Actual %, year-on-year	38%			33%
CER %, year-on-year	38%			32%
BioPharmaceuticals: total CVRM | Established ROW
Product sales
Product Sales	$ 191			$ 373
Actual %, year-on-year	(14.00%)			(8.00%)
CER %, year-on-year	(3.00%)			2%
Farxiga
Product sales
Product Sales	$ 1,940			$ 3,785
Actual %, year-on-year	29%			35%
CER %, year-on-year	32%			38%
Farxiga | US
Product sales
Product Sales	$ 394			$ 867
Actual %, year-on-year	16%			37%
Farxiga | Emerging Markets
Product sales
Product Sales	$ 763			$ 1,474
Actual %, year-on-year	32%			37%
CER %, year-on-year	39%			44%
Farxiga | Europe
Product sales
Product Sales	$ 680			$ 1,233
Actual %, year-on-year	49%			45%
CER %, year-on-year	49%			44%
Farxiga | Established ROW
Product sales
Product Sales	$ 103			$ 211
Actual %, year-on-year	(23.00%)			(15.00%)
CER %, year-on-year	(14.00%)			(5.00%)
Brilinta
Product sales
Product Sales	$ 342			$ 665
Actual %, year-on-year	3%
CER %, year-on-year	5%			2%
Brilinta | US
Product sales
Product Sales	$ 191			$ 354
Actual %, year-on-year	7%			(1.00%)
Brilinta | Emerging Markets
Product sales
Product Sales	$ 78			$ 166
Actual %, year-on-year	(1.00%)			4%
CER %, year-on-year	6%			14%
Brilinta | Europe
Product sales
Product Sales	$ 69			$ 136
Actual %, year-on-year	1%
CER %, year-on-year	1%			(1.00%)
Brilinta | Established ROW
Product sales
Product Sales	$ 4			$ 9
Actual %, year-on-year	(38.00%)			(26.00%)
CER %, year-on-year	(23.00%)			(19.00%)
Crestor
Product sales
Product Sales	$ 292			$ 589
Actual %, year-on-year	4%			1%
CER %, year-on-year	11%			6%
Crestor | US
Product sales
Product Sales	$ 12			$ 22
Actual %, year-on-year	(2.00%)			(18.00%)
Crestor | Emerging Markets
Product sales
Product Sales	$ 234			$ 475
Actual %, year-on-year	8%			4%
CER %, year-on-year	14%			9%
Crestor | Europe
Product sales
Product Sales	$ 10			$ 22
Actual %, year-on-year	(34.00%)			(30.00%)
CER %, year-on-year	(32.00%)			(29.00%)
Crestor | Established ROW
Product sales
Product Sales	$ 36			$ 70
Actual %, year-on-year	3%			3%
CER %, year-on-year	15%			13%
Seloken/Toprol-XL
Product sales
Product Sales	$ 150			$ 315
Actual %, year-on-year	(8.00%)			(8.00%)
CER %, year-on-year				(1.00%)
Seloken/Toprol-XL | Emerging Markets
Product sales
Product Sales	$ 146			$ 307
Actual %, year-on-year	(8.00%)			(8.00%)
CER %, year-on-year				(1.00%)
Seloken/Toprol-XL | Europe
Product sales
Product Sales	$ 3			$ 6
Actual %, year-on-year	46%			4%
CER %, year-on-year	53%			7%
Seloken/Toprol-XL | Established ROW
Product sales
Product Sales	$ 1			$ 2
Actual %, year-on-year	(40.00%)			(39.00%)
CER %, year-on-year	(38.00%)			(37.00%)
Lokelma
Product sales
Product Sales	$ 136			$ 249
Actual %, year-on-year	36%			26%
CER %, year-on-year	41%			30%
Lokelma | US
Product sales
Product Sales	$ 64			$ 115
Actual %, year-on-year	29%			10%
Lokelma | Emerging Markets
Product sales
Product Sales	$ 21			$ 42
Actual %, year-on-year	68%			75%
CER %, year-on-year	78%			83%
Lokelma | Europe
Product sales
Product Sales	$ 23			$ 41
Actual %, year-on-year	63%			62%
CER %, year-on-year	64%			61%
Lokelma | Established ROW
Product sales
Product Sales	$ 28			$ 51
Actual %, year-on-year	16%			16%
CER %, year-on-year	33%			31%
roxadustat
Product sales
Product Sales	$ 88			$ 163
Actual %, year-on-year	20%			22%
CER %, year-on-year	26%			27%
roxadustat | Emerging Markets
Product sales
Product Sales	$ 88			$ 163
Actual %, year-on-year	20%			22%
CER %, year-on-year	26%			27%
Andexxa
Product sales
Product Sales	$ 59			$ 105
Actual %, year-on-year	29%			18%
CER %, year-on-year	35%			21%
Andexxa | US
Product sales
Product Sales	$ 22			$ 42
Actual %, year-on-year	34%			14%
Andexxa | Emerging Markets
Product sales
Product Sales	$ 1			$ 2
Andexxa | Europe
Product sales
Product Sales	$ 22			$ 40
Actual %, year-on-year	51%			38%
CER %, year-on-year	51%			36%
Andexxa | Established ROW
Product sales
Product Sales	$ 14			$ 21
Actual %, year-on-year	(6.00%)			(9.00%)
CER %, year-on-year	8%			4%
Wainua
Product sales
Product Sales	$ 16			$ 21
Wainua | US
Product sales
Product Sales	16			21
CVRM, Others
Product sales
Product Sales	$ 130			$ 272
Actual %, year-on-year	(26.00%)			(30.00%)
CER %, year-on-year	(24.00%)			(28.00%)
CVRM, Others | US
Product sales
Product Sales	$ 36			$ 62
Actual %, year-on-year	(45.00%)			(50.00%)
CVRM, Others | Emerging Markets
Product sales
Product Sales	$ 53			$ 120
Actual %, year-on-year	(19.00%)			(27.00%)
CER %, year-on-year	(14.00%)			(22.00%)
CVRM, Others | Europe
Product sales
Product Sales	$ 36			$ 81
Actual %, year-on-year	(9.00%)			(10.00%)
CER %, year-on-year	(8.00%)			(10.00%)
CVRM, Others | Established ROW
Product sales
Product Sales	$ 5			$ 9
Actual %, year-on-year	(14.00%)			(7.00%)
CER %, year-on-year	(12.00%)			(5.00%)
BioPharmaceuticals: total Respiratory & Immunology
Product sales
Product Sales	$ 1,797			$ 3,601
Actual %, year-on-year	21%			17%
CER %, year-on-year	24%			20%
BioPharmaceuticals: total Respiratory & Immunology | US
Product sales
Product Sales	$ 830			$ 1,567
Actual %, year-on-year	23%			21%
BioPharmaceuticals: total Respiratory & Immunology | Emerging Markets
Product sales
Product Sales	$ 444			$ 1,032
Actual %, year-on-year	23%			16%
CER %, year-on-year	34%			23%
BioPharmaceuticals: total Respiratory & Immunology | Europe
Product sales
Product Sales	$ 350			$ 680
Actual %, year-on-year	21%			17%
CER %, year-on-year	21%			16%
BioPharmaceuticals: total Respiratory & Immunology | Established ROW
Product sales
Product Sales	$ 173			$ 322
Actual %, year-on-year	8%			7%
CER %, year-on-year	14%			12%
Symbicort
Product sales
Product Sales	$ 722			$ 1,491
Actual %, year-on-year	20%			16%
CER %, year-on-year	25%			19%
Symbicort | US
Product sales
Product Sales	$ 299			$ 598
Actual %, year-on-year	49%			38%
Symbicort | Emerging Markets
Product sales
Product Sales	$ 197			$ 450
Actual %, year-on-year	12%			11%
CER %, year-on-year	25%			21%
Symbicort | Europe
Product sales
Product Sales	$ 143			$ 286
Actual %, year-on-year	4%
CER %, year-on-year	5%			(1.00%)
Symbicort | Established ROW
Product sales
Product Sales	$ 83			$ 157
Actual %, year-on-year	(4.00%)			(4.00%)
CER %, year-on-year	(1.00%)			(2.00%)
Fasenra
Product sales
Product Sales	$ 423			$ 781
Actual %, year-on-year	4%			5%
CER %, year-on-year	5%			6%
Fasenra | US
Product sales
Product Sales	$ 268			$ 478
Actual %, year-on-year				2%
Fasenra | Emerging Markets
Product sales
Product Sales	$ 19			$ 41
Actual %, year-on-year	33%			45%
CER %, year-on-year	46%			53%
Fasenra | Europe
Product sales
Product Sales	$ 99			$ 192
Actual %, year-on-year	11%			9%
CER %, year-on-year	11%			8%
Fasenra | Established ROW
Product sales
Product Sales	$ 37			$ 70
Actual %, year-on-year	3%			(2.00%)
CER %, year-on-year	11%			6%
Pulmicort
Product sales
Product Sales	$ 155			$ 379
Actual %, year-on-year	25%			10%
CER %, year-on-year	30%			14%
Pulmicort | US
Product sales
Product Sales	$ 3			$ 8
Actual %, year-on-year	(53.00%)			(53.00%)
Pulmicort | Emerging Markets
Product sales
Product Sales	$ 126			$ 317
Actual %, year-on-year	40%			16%
CER %, year-on-year	47%			22%
Pulmicort | Europe
Product sales
Product Sales	$ 17			$ 37
Actual %, year-on-year	6%			1%
CER %, year-on-year	2%			(1.00%)
Pulmicort | Established ROW
Product sales
Product Sales	$ 9			$ 17
Actual %, year-on-year	(18.00%)			(13.00%)
CER %, year-on-year	(13.00%)			(9.00%)
Breztri
Product sales
Product Sales	$ 235			$ 454
Actual %, year-on-year	44%			48%
CER %, year-on-year	47%			51%
Breztri | US
Product sales
Product Sales	$ 120			$ 225
Actual %, year-on-year	43%			37%
Breztri | Emerging Markets
Product sales
Product Sales	$ 61			$ 131
Actual %, year-on-year	42%			61%
CER %, year-on-year	49%			69%
Breztri | Europe
Product sales
Product Sales	$ 35			$ 65
Actual %, year-on-year	68%			80%
CER %, year-on-year	69%			79%
Breztri | Established ROW
Product sales
Product Sales	$ 19			$ 33
Actual %, year-on-year	26%			33%
CER %, year-on-year	37%			44%
Tezspire
Product sales
Product Sales	$ 57			$ 100
Tezspire | Emerging Markets
Product sales
Product Sales	3			5
Tezspire | Europe
Product sales
Product Sales	35			61
Tezspire | Established ROW
Product sales
Product Sales	19			34
Saphnelo
Product sales
Product Sales	$ 112			$ 203
Actual %, year-on-year	65%			77%
CER %, year-on-year	65%			77%
Saphnelo | US
Product sales
Product Sales	$ 101			$ 184
Actual %, year-on-year	59%			71%
Saphnelo | Emerging Markets
Product sales
Product Sales	$ 1			$ 2
Actual %, year-on-year	28%
Saphnelo | Europe
Product sales
Product Sales	$ 6			10
Saphnelo | Established ROW
Product sales
Product Sales	$ 4			$ 7
Actual %, year-on-year	90%			86%
CER %, year-on-year	86%			91%
Airsupra
Product sales
Product Sales	$ 14			$ 21
Airsupra | US
Product sales
Product Sales	14			21
Respiratory, Others
Product sales
Product Sales	$ 79			$ 172
Actual %, year-on-year	(24.00%)			(27.00%)
CER %, year-on-year	(22.00%)			(26.00%)
Respiratory, Others | US
Product sales
Product Sales	$ 25			$ 53
Actual %, year-on-year	(52.00%)			(47.00%)
Respiratory, Others | Emerging Markets
Product sales
Product Sales	$ 37			$ 86
Actual %, year-on-year	7%			(18.00%)
CER %, year-on-year	12%			(14.00%)
Respiratory, Others | Europe
Product sales
Product Sales	$ 15			$ 29
Actual %, year-on-year	2%			3%
CER %, year-on-year	3%			2%
Respiratory, Others | Established ROW
Product sales
Product Sales	$ 2			$ 4
Actual %, year-on-year	(6.00%)			(12.00%)
CER %, year-on-year	(4.00%)			(10.00%)
BioPharmaceuticals: Total V&I
Product sales
Product Sales	$ 112			$ 324
Actual %, year-on-year	28%			(27.00%)
CER %, year-on-year	42%			(24.00%)
BioPharmaceuticals: Total V&I | US
Product sales
Product Sales	$ 28			$ 55
BioPharmaceuticals: Total V&I | Emerging Markets
Product sales
Product Sales	$ 41			$ 131
Actual %, year-on-year	(10.00%)			(12.00%)
CER %, year-on-year	4%			(7.00%)
BioPharmaceuticals: Total V&I | Europe
Product sales
Product Sales	$ 7			$ 81
Actual %, year-on-year	(55.00%)			(28.00%)
CER %, year-on-year	(53.00%)			(30.00%)
BioPharmaceuticals: Total V&I | Established ROW
Product sales
Product Sales	$ 36			$ 57
Actual %, year-on-year	36%			(68.00%)
CER %, year-on-year	55%			(65.00%)
Synagis
Product sales
Product Sales	$ 81			$ 253
Actual %, year-on-year	(6.00%)			(11.00%)
CER %, year-on-year	8%			(6.00%)
Synagis | US
Product sales
Product sales net of reversals	$ (1)			$ (1)
Synagis | Emerging Markets
Product sales
Product Sales	$ 41			$ 131
Actual %, year-on-year	(16.00%)			4%
CER %, year-on-year	(2.00%)			10%
Synagis | Europe
Product sales
Product Sales	$ 6			$ 67
Actual %, year-on-year	(42.00%)			(27.00%)
CER %, year-on-year	(42.00%)			(29.00%)
Synagis | Established ROW
Product sales
Product Sales	$ 35			$ 56
Actual %, year-on-year	27%			(15.00%)
CER %, year-on-year	46%			(6.00%)
Beyfortus
Product sales
Product Sales	$ 28			$ 54
Beyfortus | US
Product sales
Product Sales	$ 27			$ 53
Beyfortus | Europe
Product sales
Actual %, year-on-year				(81.00%)
CER %, year-on-year	(91.00%)			(61.00%)
Beyfortus | Established ROW
Product sales
Product Sales	$ 1			$ 1
FluMist
Product sales
Product Sales	2			8
FluMist | US
Product sales
Product Sales	$ 2			3
FluMist | Europe
Product sales
Product Sales				$ 5
Actual %, year-on-year	(26.00%)
CER %, year-on-year	(21.00%)			97%
Covid-19 mAbs
Product sales
Product Sales	$ 1			$ 3
Actual %, year-on-year				(98.00%)
CER %, year-on-year				(98.00%)
Covid-19 mAbs | Europe
Product sales
Product Sales	$ 1			$ 3
Actual %, year-on-year	(65.00%)			(58.00%)
CER %, year-on-year	(64.00%)			(59.00%)
Covid-19 mAbs | Established ROW
Product sales
Actual %, year-on-year	(99.00%)
CER %, year-on-year	(99.00%)
V&I, Others
Product sales
Product Sales				$ 6
Actual %, year-on-year				(79.00%)
CER %, year-on-year				(80.00%)
V&I, Others | Europe
Product sales
Product Sales				$ 6
Actual %, year-on-year				(41.00%)
CER %, year-on-year				(43.00%)
Total rare diseases
Product sales
Product Sales	$ 2,147			$ 4,243
Actual %, year-on-year	10%			11%
CER %, year-on-year	14%			15%
Total rare diseases | US
Product sales
Product Sales	$ 1,311			$ 2,517
Actual %, year-on-year	10%			10%
Total rare diseases | Emerging Markets
Product sales
Product Sales	$ 203			$ 454
Actual %, year-on-year	35%			40%
CER %, year-on-year	67%			70%
Total rare diseases | Europe
Product sales
Product Sales	$ 392			$ 794
Actual %, year-on-year	3%			3%
CER %, year-on-year	3%			2%
Total rare diseases | Established ROW
Product sales
Product Sales	$ 241			$ 478
Actual %, year-on-year	7%			9%
CER %, year-on-year	18%			20%
Ultomiris
Product sales
Product Sales	$ 946			$ 1,804
Actual %, year-on-year	33%			32%
CER %, year-on-year	36%			35%
Ultomiris | US
Product sales
Product Sales	$ 550			$ 1,032
Actual %, year-on-year	27%			27%
Ultomiris | Emerging Markets
Product sales
Product Sales	$ 35			$ 66
Ultomiris | Europe
Product sales
Product Sales	$ 209			$ 411
Actual %, year-on-year	38%			32%
CER %, year-on-year	38%			31%
Ultomiris | Established ROW
Product sales
Product Sales	$ 152			$ 295
Actual %, year-on-year	38%			42%
CER %, year-on-year	56%			58%
Soliris
Product sales
Product Sales	$ 700			$ 1,439
Actual %, year-on-year	(14.00%)			(13.00%)
CER %, year-on-year	(8.00%)			(8.00%)
Soliris | US
Product sales
Product Sales	$ 398			$ 808
Actual %, year-on-year	(11.00%)			(9.00%)
Soliris | Emerging Markets
Product sales
Product Sales	$ 129			$ 255
Actual %, year-on-year	30%			19%
CER %, year-on-year	74%			54%
Soliris | Europe
Product sales
Product Sales	$ 118			$ 260
Actual %, year-on-year	(36.00%)			(29.00%)
CER %, year-on-year	(36.00%)			(30.00%)
Soliris | Established ROW
Product sales
Product Sales	$ 55			$ 116
Actual %, year-on-year	(36.00%)			(33.00%)
CER %, year-on-year	(33.00%)			(30.00%)
Strensiq
Product sales
Product Sales	$ 340			$ 653
Actual %, year-on-year	13%			16%
CER %, year-on-year	14%			18%
Strensiq | US
Product sales
Product Sales	$ 283			$ 529
Actual %, year-on-year	14%			17%
Strensiq | Emerging Markets
Product sales
Product Sales	$ 10			$ 31
Actual %, year-on-year	7%			30%
CER %, year-on-year	15%			47%
Strensiq | Europe
Product sales
Product Sales	$ 24			$ 48
Actual %, year-on-year	13%			14%
CER %, year-on-year	13%			12%
Strensiq | Established ROW
Product sales
Product Sales	$ 23			$ 45
Actual %, year-on-year	4%			4%
CER %, year-on-year	17%			15%
Koselugo
Product sales
Product Sales	$ 114			$ 247
Actual %, year-on-year	43%			55%
CER %, year-on-year	45%			64%
Koselugo | US
Product sales
Product Sales	$ 55			$ 101
Actual %, year-on-year	13%			13%
Koselugo | Emerging Markets
Product sales
Product Sales	$ 24			$ 83
Actual %, year-on-year	73%
CER %, year-on-year	80%
Koselugo | Europe
Product sales
Product Sales	$ 26			$ 45
Actual %, year-on-year				95%
CER %, year-on-year				92%
Koselugo | Established ROW
Product sales
Product Sales	$ 9			$ 18
Actual %, year-on-year	63%
CER %, year-on-year	85%
Kanuma
Product sales
Product Sales	$ 47			$ 100
Actual %, year-on-year	3%			17%
CER %, year-on-year	8%			20%
Kanuma | US
Product sales
Product Sales	$ 25			$ 47
Actual %, year-on-year	21%			18%
Kanuma | Emerging Markets
Product sales
Product Sales	$ 5			$ 19
Actual %, year-on-year	(54.00%)			7%
CER %, year-on-year	(49.00%)			20%
Kanuma | Europe
Product sales
Product Sales	$ 15			$ 30
Actual %, year-on-year	28%			24%
CER %, year-on-year	33%			25%
Kanuma | Established ROW
Product sales
Product Sales	$ 2			$ 4
Actual %, year-on-year	11%			11%
CER %, year-on-year	41%			20%
Total Other medicines
Product sales
Product Sales	$ 267			$ 560
Actual %, year-on-year	(11.00%)			(9.00%)
CER %, year-on-year	(5.00%)			(2.00%)
Total Other medicines | US
Product sales
Product Sales	$ 28			$ 52
Actual %, year-on-year	(13.00%)			(24.00%)
Total Other medicines | Emerging Markets
Product sales
Product Sales	$ 179			$ 385
Actual %, year-on-year	(3.00%)			(1.00%)
CER %, year-on-year	5%			8%
Total Other medicines | Europe
Product sales
Product Sales	$ 24			$ 53
Actual %, year-on-year	(7.00%)			10%
CER %, year-on-year	(7.00%)			10%
Total Other medicines | Established ROW
Product sales
Product Sales	$ 36			$ 70
Actual %, year-on-year	(38.00%)			(35.00%)
CER %, year-on-year	(32.00%)			(29.00%)
Nexium
Product sales
Product Sales	$ 219			$ 459
Actual %, year-on-year	(12.00%)			(7.00%)
CER %, year-on-year	(5.00%)			1%
Nexium | US
Product sales
Product Sales	$ 25			$ 47
Actual %, year-on-year	(17.00%)			(22.00%)
Nexium | Emerging Markets
Product sales
Product Sales	$ 146			$ 318
Actual %, year-on-year	(2.00%)			4%
CER %, year-on-year	7%			15%
Nexium | Europe
Product sales
Product Sales	$ 13			$ 26
Actual %, year-on-year	(5.00%)			3%
CER %, year-on-year	(5.00%)			2%
Nexium | Established ROW
Product sales
Product Sales	$ 35			$ 68
Actual %, year-on-year	(37.00%)			(34.00%)
CER %, year-on-year	(32.00%)			(28.00%)
Other, Others
Product sales
Product Sales	$ 48			$ 101
Actual %, year-on-year	(9.00%)			(17.00%)
CER %, year-on-year	(6.00%)			(14.00%)
Other, Others | US
Product sales
Product Sales	$ 3			$ 5
Actual %, year-on-year	39%			(40.00%)
Other, Others | Emerging Markets
Product sales
Product Sales	$ 33			$ 67
Actual %, year-on-year	(8.00%)			(22.00%)
CER %, year-on-year	(4.00%)			(18.00%)
Other, Others | Europe
Product sales
Product Sales	$ 11			$ 27
Actual %, year-on-year	(9.00%)			18%
CER %, year-on-year	(9.00%)			19%
Other, Others | Established ROW
Product sales
Product Sales	$ 1			$ 2
Actual %, year-on-year	(54.00%)			(53.00%)
CER %, year-on-year	(49.00%)			(49.00%)
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP.

Q2 2024 Product Sales year-on_2

Q2 2024 Product Sales year-on-year analysis (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2024		Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Product sales
Product Sales	$ 12,452	[1]	$ 10,882	$ 24,629	$ 21,448
Actual %, year-on-year	14%			15%
CER %, year-on-year	18%			18%
US
Product sales
Product Sales	$ 5,234			$ 10,061
Actual %, year-on-year	16%			17%
Emerging Markets
Product sales
Product Sales	$ 3,349			$ 7,051
Actual %, year-on-year	15%			16%
CER %, year-on-year	25%			26%
Europe
Product sales
Product Sales	$ 2,631			$ 5,134
Actual %, year-on-year	23%			21%
CER %, year-on-year	23%			19%
Established ROW
Product sales
Product Sales	$ 1,238			$ 2,383
Actual %, year-on-year	(5.00%)			(6.00%)
CER %, year-on-year	5%			3%
Total Oncology
Product sales
Product Sales	$ 4,976			$ 9,737
Actual %, year-on-year	14%			17%
CER %, year-on-year	18%			21%
Total Oncology | US
Product sales
Product Sales	$ 2,302			$ 4,387
Actual %, year-on-year	17%			20%
Total Oncology | Emerging Markets
Product sales
Product Sales	$ 1,098			$ 2,300
Actual %, year-on-year	11%			18%
CER %, year-on-year	22%			28%
Total Oncology | Europe
Product sales
Product Sales	$ 1,015			$ 1,967
Actual %, year-on-year	24%			25%
CER %, year-on-year	24%			23%
Total Oncology | Established ROW
Product sales
Product Sales	$ 561			$ 1,083
Actual %, year-on-year	(9.00%)			(2.00%)
CER %, year-on-year	2%			8%
Tagrisso
Product sales
Product Sales	$ 1,608			$ 3,203
Actual %, year-on-year	8%			10%
CER %, year-on-year	12%			13%
Tagrisso | US
Product sales
Product Sales	$ 658			$ 1,282
Actual %, year-on-year	13%			16%
Tagrisso | Emerging Markets
Product sales
Product Sales	$ 432			$ 919
Actual %, year-on-year	6%			8%
CER %, year-on-year	15%			16%
Tagrisso | Europe
Product sales
Product Sales	$ 327			$ 628
Actual %, year-on-year	15%			16%
CER %, year-on-year	15%			15%
Tagrisso | Established ROW
Product sales
Product Sales	$ 191			$ 374
Actual %, year-on-year	(12.00%)			(11.00%)
CER %, year-on-year	(1.00%)			(2.00%)
Imfinzi
Product sales
Product Sales	$ 1,147			$ 2,259
Actual %, year-on-year	13%			20%
CER %, year-on-year	18%			25%
Imfinzi | US
Product sales
Product Sales	$ 620			$ 1,202
Actual %, year-on-year	15%			17%
Imfinzi | Emerging Markets
Product sales
Product Sales	$ 117			$ 245
Actual %, year-on-year	16%			35%
CER %, year-on-year	39%			58%
Imfinzi | Europe
Product sales
Product Sales	$ 227			$ 459
Actual %, year-on-year	33%			38%
CER %, year-on-year	33%			36%
Imfinzi | Established ROW
Product sales
Product Sales	$ 183			$ 353
Actual %, year-on-year	(9.00%)			7%
CER %, year-on-year	3%			19%
Lynparza
Product sales
Product Sales	$ 744			$ 1,450
Actual %, year-on-year	4%			6%
CER %, year-on-year	7%			9%
Lynparza | US
Product sales
Product Sales	$ 319			$ 607
Actual %, year-on-year	3%			5%
Lynparza | Emerging Markets
Product sales
Product Sales	$ 153			$ 320
Actual %, year-on-year	8%			15%
CER %, year-on-year	18%			26%
Lynparza | Europe
Product sales
Product Sales	$ 206			$ 398
Actual %, year-on-year	10%			9%
CER %, year-on-year	11%			8%
Lynparza | Established ROW
Product sales
Product Sales	$ 66			$ 125
Actual %, year-on-year	(15.00%)			(14.00%)
CER %, year-on-year	(6.00%)			(6.00%)
Calquence
Product sales
Product Sales	$ 790			$ 1,508
Actual %, year-on-year	21%			27%
CER %, year-on-year	22%			28%
Calquence | US
Product sales
Product Sales	$ 554			$ 1,048
Actual %, year-on-year	14%			21%
Calquence | Emerging Markets
Product sales
Product Sales	$ 36			$ 75
Actual %, year-on-year	51%			82%
CER %, year-on-year	72%
Calquence | Europe
Product sales
Product Sales	$ 167			$ 320
Actual %, year-on-year	42%			42%
CER %, year-on-year	43%			41%
Calquence | Established ROW
Product sales
Product Sales	$ 33			$ 65
Actual %, year-on-year	20%			30%
CER %, year-on-year	23%			34%
Enhertu
Product sales
Product Sales	$ 127			$ 249
Actual %, year-on-year	89%
CER %, year-on-year	99%
Enhertu | Emerging Markets
Product sales
Product Sales	$ 77			161
Actual %, year-on-year	60%
CER %, year-on-year	72%
Enhertu | Europe
Product sales
Product Sales	$ 31			57
Enhertu | Established ROW
Product sales
Product Sales	19			31
Orpathys
Product sales
Product Sales	$ 12			$ 25
Actual %, year-on-year	(7.00%)			14%
CER %, year-on-year	(3.00%)			19%
Orpathys | Emerging Markets
Product sales
Product Sales	$ 12			$ 25
Actual %, year-on-year	(7.00%)			14%
CER %, year-on-year	(3.00%)			19%
Truqap
Product sales
Product Sales	$ 92			$ 142
Truqap | US
Product sales
Product Sales	91			141
Truqap | Established ROW
Product sales
Product Sales	1			1
Zoladex
Product sales
Product Sales	$ 273			$ 549
Actual %, year-on-year	17%			19%
CER %, year-on-year	25%			27%
Zoladex | US
Product sales
Product Sales	$ 5			$ 8
Actual %, year-on-year	29%			20%
Zoladex | Emerging Markets
Product sales
Product Sales	$ 201			$ 415
Actual %, year-on-year	17%			22%
CER %, year-on-year	28%			31%
Zoladex | Europe
Product sales
Product Sales	$ 42			$ 77
Actual %, year-on-year	23%			16%
CER %, year-on-year	21%			14%
Zoladex | Established ROW
Product sales
Product Sales	$ 25			$ 49
Actual %, year-on-year	6%			2%
CER %, year-on-year	17%			12%
Oncology, Others
Product sales
Product Sales	$ 109			$ 216
Actual %, year-on-year	(17.00%)			(21.00%)
CER %, year-on-year	(11.00%)			(15.00%)
Oncology, Others | US
Product sales
Product Sales	$ 6			$ 11
Actual %, year-on-year	24%			6%
Oncology, Others | Emerging Markets
Product sales
Product Sales	$ 66			$ 133
Actual %, year-on-year	(16.00%)			(21.00%)
CER %, year-on-year	(10.00%)			(15.00%)
Oncology, Others | Europe
Product sales
Product Sales	$ 7			$ 12
Actual %, year-on-year	(11.00%)			(36.00%)
CER %, year-on-year	(10.00%)			(36.00%)
Oncology, Others | Established ROW
Product sales
Product Sales	$ 30			$ 60
Actual %, year-on-year	(26.00%)			(21.00%)
CER %, year-on-year	(16.00%)			(12.00%)
BioPharmaceuticals: total CVRM
Product sales
Product Sales	$ 3,153			$ 6,164
Actual %, year-on-year	18%			18%
CER %, year-on-year	22%			22%
BioPharmaceuticals: total CVRM | US
Product sales
Product Sales	$ 735			$ 1,483
Actual %, year-on-year	11%			16%
BioPharmaceuticals: total CVRM | Emerging Markets
Product sales
Product Sales	$ 1,384			$ 2,749
Actual %, year-on-year	17%			17%
CER %, year-on-year	24%			24%
BioPharmaceuticals: total CVRM | Europe
Product sales
Product Sales	$ 843			$ 1,559
Actual %, year-on-year	38%			33%
CER %, year-on-year	38%			32%
BioPharmaceuticals: total CVRM | Established ROW
Product sales
Product Sales	$ 191			$ 373
Actual %, year-on-year	(14.00%)			(8.00%)
CER %, year-on-year	(3.00%)			2%
Farxiga
Product sales
Product Sales	$ 1,940			$ 3,785
Actual %, year-on-year	29%			35%
CER %, year-on-year	32%			38%
Farxiga | US
Product sales
Product Sales	$ 394			$ 867
Actual %, year-on-year	16%			37%
Farxiga | Emerging Markets
Product sales
Product Sales	$ 763			$ 1,474
Actual %, year-on-year	32%			37%
CER %, year-on-year	39%			44%
Farxiga | Europe
Product sales
Product Sales	$ 680			$ 1,233
Actual %, year-on-year	49%			45%
CER %, year-on-year	49%			44%
Farxiga | Established ROW
Product sales
Product Sales	$ 103			$ 211
Actual %, year-on-year	(23.00%)			(15.00%)
CER %, year-on-year	(14.00%)			(5.00%)
Brilinta
Product sales
Product Sales	$ 342			$ 665
Actual %, year-on-year	3%
CER %, year-on-year	5%			2%
Brilinta | US
Product sales
Product Sales	$ 191			$ 354
Actual %, year-on-year	7%			(1.00%)
Brilinta | Emerging Markets
Product sales
Product Sales	$ 78			$ 166
Actual %, year-on-year	(1.00%)			4%
CER %, year-on-year	6%			14%
Brilinta | Europe
Product sales
Product Sales	$ 69			$ 136
Actual %, year-on-year	1%
CER %, year-on-year	1%			(1.00%)
Brilinta | Established ROW
Product sales
Product Sales	$ 4			$ 9
Actual %, year-on-year	(38.00%)			(26.00%)
CER %, year-on-year	(23.00%)			(19.00%)
Lokelma
Product sales
Product Sales	$ 136			$ 249
Actual %, year-on-year	36%			26%
CER %, year-on-year	41%			30%
Lokelma | US
Product sales
Product Sales	$ 64			$ 115
Actual %, year-on-year	29%			10%
Lokelma | Emerging Markets
Product sales
Product Sales	$ 21			$ 42
Actual %, year-on-year	68%			75%
CER %, year-on-year	78%			83%
Lokelma | Europe
Product sales
Product Sales	$ 23			$ 41
Actual %, year-on-year	63%			62%
CER %, year-on-year	64%			61%
Lokelma | Established ROW
Product sales
Product Sales	$ 28			$ 51
Actual %, year-on-year	16%			16%
CER %, year-on-year	33%			31%
roxadustat
Product sales
Product Sales	$ 88			$ 163
Actual %, year-on-year	20%			22%
CER %, year-on-year	26%			27%
roxadustat | Emerging Markets
Product sales
Product Sales	$ 88			$ 163
Actual %, year-on-year	20%			22%
CER %, year-on-year	26%			27%
Crestor.
Product sales
Product Sales	$ 292			$ 589
Actual %, year-on-year	4%			1%
CER %, year-on-year	11%			6%
Crestor. | US
Product sales
Product Sales	$ 12			$ 22
Actual %, year-on-year	(2.00%)			(18.00%)
Crestor. | Emerging Markets
Product sales
Product Sales	$ 234			$ 475
Actual %, year-on-year	8%			4%
CER %, year-on-year	14%			9%
Crestor. | Europe
Product sales
Product Sales	$ 10			$ 22
Actual %, year-on-year	(34.00%)			(30.00%)
CER %, year-on-year	(32.00%)			(29.00%)
Crestor. | Established ROW
Product sales
Product Sales	$ 36			$ 70
Actual %, year-on-year	3%			3%
CER %, year-on-year	15%			13%
Seloken/Toprol-XL
Product sales
Product Sales	$ 150			$ 315
Actual %, year-on-year	(8.00%)			(8.00%)
CER %, year-on-year				(1.00%)
Seloken/Toprol-XL | Emerging Markets
Product sales
Product Sales	$ 146			$ 307
Actual %, year-on-year	(8.00%)			(8.00%)
CER %, year-on-year				(1.00%)
Seloken/Toprol-XL | Europe
Product sales
Product Sales	$ 3			$ 6
Actual %, year-on-year	46%			4%
CER %, year-on-year	53%			7%
Seloken/Toprol-XL | Established ROW
Product sales
Product Sales	$ 1			$ 2
Actual %, year-on-year	(40.00%)			(39.00%)
CER %, year-on-year	(38.00%)			(37.00%)
CVRM, Others
Product sales
Product Sales	$ 130			$ 272
Actual %, year-on-year	(26.00%)			(30.00%)
CER %, year-on-year	(24.00%)			(28.00%)
CVRM, Others | US
Product sales
Product Sales	$ 36			$ 62
Actual %, year-on-year	(45.00%)			(50.00%)
CVRM, Others | Emerging Markets
Product sales
Product Sales	$ 53			$ 120
Actual %, year-on-year	(19.00%)			(27.00%)
CER %, year-on-year	(14.00%)			(22.00%)
CVRM, Others | Europe
Product sales
Product Sales	$ 36			$ 81
Actual %, year-on-year	(9.00%)			(10.00%)
CER %, year-on-year	(8.00%)			(10.00%)
CVRM, Others | Established ROW
Product sales
Product Sales	$ 5			$ 9
Actual %, year-on-year	(14.00%)			(7.00%)
CER %, year-on-year	(12.00%)			(5.00%)
BioPharmaceuticals: total Respiratory & Immunology
Product sales
Product Sales	$ 1,797			$ 3,601
Actual %, year-on-year	21%			17%
CER %, year-on-year	24%			20%
BioPharmaceuticals: total Respiratory & Immunology | US
Product sales
Product Sales	$ 830			$ 1,567
Actual %, year-on-year	23%			21%
BioPharmaceuticals: total Respiratory & Immunology | Emerging Markets
Product sales
Product Sales	$ 444			$ 1,032
Actual %, year-on-year	23%			16%
CER %, year-on-year	34%			23%
BioPharmaceuticals: total Respiratory & Immunology | Europe
Product sales
Product Sales	$ 350			$ 680
Actual %, year-on-year	21%			17%
CER %, year-on-year	21%			16%
BioPharmaceuticals: total Respiratory & Immunology | Established ROW
Product sales
Product Sales	$ 173			$ 322
Actual %, year-on-year	8%			7%
CER %, year-on-year	14%			12%
Symbicort
Product sales
Product Sales	$ 722			$ 1,491
Actual %, year-on-year	20%			16%
CER %, year-on-year	25%			19%
Symbicort | US
Product sales
Product Sales	$ 299			$ 598
Actual %, year-on-year	49%			38%
Symbicort | Emerging Markets
Product sales
Product Sales	$ 197			$ 450
Actual %, year-on-year	12%			11%
CER %, year-on-year	25%			21%
Symbicort | Europe
Product sales
Product Sales	$ 143			$ 286
Actual %, year-on-year	4%
CER %, year-on-year	5%			(1.00%)
Symbicort | Established ROW
Product sales
Product Sales	$ 83			$ 157
Actual %, year-on-year	(4.00%)			(4.00%)
CER %, year-on-year	(1.00%)			(2.00%)
Fasenra
Product sales
Product Sales	$ 423			$ 781
Actual %, year-on-year	4%			5%
CER %, year-on-year	5%			6%
Fasenra | US
Product sales
Product Sales	$ 268			$ 478
Actual %, year-on-year				2%
Fasenra | Emerging Markets
Product sales
Product Sales	$ 19			$ 41
Actual %, year-on-year	33%			45%
CER %, year-on-year	46%			53%
Fasenra | Europe
Product sales
Product Sales	$ 99			$ 192
Actual %, year-on-year	11%			9%
CER %, year-on-year	11%			8%
Fasenra | Established ROW
Product sales
Product Sales	$ 37			$ 70
Actual %, year-on-year	3%			(2.00%)
CER %, year-on-year	11%			6%
Breztri
Product sales
Product Sales	$ 235			$ 454
Actual %, year-on-year	44%			48%
CER %, year-on-year	47%			51%
Breztri | US
Product sales
Product Sales	$ 120			$ 225
Actual %, year-on-year	43%			37%
Breztri | Emerging Markets
Product sales
Product Sales	$ 61			$ 131
Actual %, year-on-year	42%			61%
CER %, year-on-year	49%			69%
Breztri | Europe
Product sales
Product Sales	$ 35			$ 65
Actual %, year-on-year	68%			80%
CER %, year-on-year	69%			79%
Breztri | Established ROW
Product sales
Product Sales	$ 19			$ 33
Actual %, year-on-year	26%			33%
CER %, year-on-year	37%			44%
Saphnelo
Product sales
Product Sales	$ 112			$ 203
Actual %, year-on-year	65%			77%
CER %, year-on-year	65%			77%
Saphnelo | US
Product sales
Product Sales	$ 101			$ 184
Actual %, year-on-year	59%			71%
Saphnelo | Emerging Markets
Product sales
Product Sales	$ 1			$ 2
Actual %, year-on-year	28%
Saphnelo | Europe
Product sales
Product Sales	$ 6			10
Saphnelo | Established ROW
Product sales
Product Sales	$ 4			$ 7
Actual %, year-on-year	90%			86%
CER %, year-on-year	86%			91%
Tezspire
Product sales
Product Sales	$ 57			$ 100
Tezspire | Emerging Markets
Product sales
Product Sales	3			5
Tezspire | Europe
Product sales
Product Sales	35			61
Tezspire | Established ROW
Product sales
Product Sales	19			34
Pulmicort
Product sales
Product Sales	$ 155			$ 379
Actual %, year-on-year	25%			10%
CER %, year-on-year	30%			14%
Pulmicort | US
Product sales
Product Sales	$ 3			$ 8
Actual %, year-on-year	(53.00%)			(53.00%)
Pulmicort | Emerging Markets
Product sales
Product Sales	$ 126			$ 317
Actual %, year-on-year	40%			16%
CER %, year-on-year	47%			22%
Pulmicort | Europe
Product sales
Product Sales	$ 17			$ 37
Actual %, year-on-year	6%			1%
CER %, year-on-year	2%			(1.00%)
Pulmicort | Established ROW
Product sales
Product Sales	$ 9			$ 17
Actual %, year-on-year	(18.00%)			(13.00%)
CER %, year-on-year	(13.00%)			(9.00%)
Respiratory, Others
Product sales
Product Sales	$ 79			$ 172
Actual %, year-on-year	(24.00%)			(27.00%)
CER %, year-on-year	(22.00%)			(26.00%)
Respiratory, Others | US
Product sales
Product Sales	$ 25			$ 53
Actual %, year-on-year	(52.00%)			(47.00%)
Respiratory, Others | Emerging Markets
Product sales
Product Sales	$ 37			$ 86
Actual %, year-on-year	7%			(18.00%)
CER %, year-on-year	12%			(14.00%)
Respiratory, Others | Europe
Product sales
Product Sales	$ 15			$ 29
Actual %, year-on-year	2%			3%
CER %, year-on-year	3%			2%
Respiratory, Others | Established ROW
Product sales
Product Sales	$ 2			$ 4
Actual %, year-on-year	(6.00%)			(12.00%)
CER %, year-on-year	(4.00%)			(10.00%)
BioPharmaceuticals: Total V&I
Product sales
Product Sales	$ 112			$ 324
Actual %, year-on-year	28%			(27.00%)
CER %, year-on-year	42%			(24.00%)
BioPharmaceuticals: Total V&I | US
Product sales
Product Sales	$ 28			$ 55
BioPharmaceuticals: Total V&I | Emerging Markets
Product sales
Product Sales	$ 41			$ 131
Actual %, year-on-year	(10.00%)			(12.00%)
CER %, year-on-year	4%			(7.00%)
BioPharmaceuticals: Total V&I | Europe
Product sales
Product Sales	$ 7			$ 81
Actual %, year-on-year	(55.00%)			(28.00%)
CER %, year-on-year	(53.00%)			(30.00%)
BioPharmaceuticals: Total V&I | Established ROW
Product sales
Product Sales	$ 36			$ 57
Actual %, year-on-year	36%			(68.00%)
CER %, year-on-year	55%			(65.00%)
Covid-19 mAbs
Product sales
Product Sales	$ 1			$ 3
Actual %, year-on-year				(98.00%)
CER %, year-on-year				(98.00%)
Covid-19 mAbs | Europe
Product sales
Product Sales	$ 1			$ 3
Actual %, year-on-year	(65.00%)			(58.00%)
CER %, year-on-year	(64.00%)			(59.00%)
Covid-19 mAbs | Established ROW
Product sales
Actual %, year-on-year	(99.00%)
CER %, year-on-year	(99.00%)
Beyfortus
Product sales
Product Sales	$ 28			$ 54
Beyfortus | US
Product sales
Product Sales	$ 27			$ 53
Beyfortus | Europe
Product sales
Actual %, year-on-year				(81.00%)
CER %, year-on-year	(91.00%)			(61.00%)
Beyfortus | Established ROW
Product sales
Product Sales	$ 1			$ 1
Synagis
Product sales
Product Sales	$ 81			$ 253
Actual %, year-on-year	(6.00%)			(11.00%)
CER %, year-on-year	8%			(6.00%)
Synagis | US
Product sales
Product sales net of reversals	$ (1)			$ (1)
Synagis | Emerging Markets
Product sales
Product Sales	$ 41			$ 131
Actual %, year-on-year	(16.00%)			4%
CER %, year-on-year	(2.00%)			10%
Synagis | Europe
Product sales
Product Sales	$ 6			$ 67
Actual %, year-on-year	(42.00%)			(27.00%)
CER %, year-on-year	(42.00%)			(29.00%)
Synagis | Established ROW
Product sales
Product Sales	$ 35			$ 56
Actual %, year-on-year	27%			(15.00%)
CER %, year-on-year	46%			(6.00%)
FluMist
Product sales
Product Sales	$ 2			$ 8
FluMist | US
Product sales
Product Sales	$ 2			3
FluMist | Europe
Product sales
Product Sales				$ 5
Actual %, year-on-year	(26.00%)
CER %, year-on-year	(21.00%)			97%
Total rare diseases
Product sales
Product Sales	$ 2,147			$ 4,243
Actual %, year-on-year	10%			11%
CER %, year-on-year	14%			15%
Total rare diseases | US
Product sales
Product Sales	$ 1,311			$ 2,517
Actual %, year-on-year	10%			10%
Total rare diseases | Emerging Markets
Product sales
Product Sales	$ 203			$ 454
Actual %, year-on-year	35%			40%
CER %, year-on-year	67%			70%
Total rare diseases | Europe
Product sales
Product Sales	$ 392			$ 794
Actual %, year-on-year	3%			3%
CER %, year-on-year	3%			2%
Total rare diseases | Established ROW
Product sales
Product Sales	$ 241			$ 478
Actual %, year-on-year	7%			9%
CER %, year-on-year	18%			20%
Soliris
Product sales
Product Sales	$ 700			$ 1,439
Actual %, year-on-year	(14.00%)			(13.00%)
CER %, year-on-year	(8.00%)			(8.00%)
Soliris | US
Product sales
Product Sales	$ 398			$ 808
Actual %, year-on-year	(11.00%)			(9.00%)
Soliris | Emerging Markets
Product sales
Product Sales	$ 129			$ 255
Actual %, year-on-year	30%			19%
CER %, year-on-year	74%			54%
Soliris | Europe
Product sales
Product Sales	$ 118			$ 260
Actual %, year-on-year	(36.00%)			(29.00%)
CER %, year-on-year	(36.00%)			(30.00%)
Soliris | Established ROW
Product sales
Product Sales	$ 55			$ 116
Actual %, year-on-year	(36.00%)			(33.00%)
CER %, year-on-year	(33.00%)			(30.00%)
Ultomiris
Product sales
Product Sales	$ 946			$ 1,804
Actual %, year-on-year	33%			32%
CER %, year-on-year	36%			35%
Ultomiris | US
Product sales
Product Sales	$ 550			$ 1,032
Actual %, year-on-year	27%			27%
Ultomiris | Emerging Markets
Product sales
Product Sales	$ 35			$ 66
Ultomiris | Europe
Product sales
Product Sales	$ 209			$ 411
Actual %, year-on-year	38%			32%
CER %, year-on-year	38%			31%
Ultomiris | Established ROW
Product sales
Product Sales	$ 152			$ 295
Actual %, year-on-year	38%			42%
CER %, year-on-year	56%			58%
Strensiq
Product sales
Product Sales	$ 340			$ 653
Actual %, year-on-year	13%			16%
CER %, year-on-year	14%			18%
Strensiq | US
Product sales
Product Sales	$ 283			$ 529
Actual %, year-on-year	14%			17%
Strensiq | Emerging Markets
Product sales
Product Sales	$ 10			$ 31
Actual %, year-on-year	7%			30%
CER %, year-on-year	15%			47%
Strensiq | Europe
Product sales
Product Sales	$ 24			$ 48
Actual %, year-on-year	13%			14%
CER %, year-on-year	13%			12%
Strensiq | Established ROW
Product sales
Product Sales	$ 23			$ 45
Actual %, year-on-year	4%			4%
CER %, year-on-year	17%			15%
Koselugo
Product sales
Product Sales	$ 114			$ 247
Actual %, year-on-year	43%			55%
CER %, year-on-year	45%			64%
Koselugo | US
Product sales
Product Sales	$ 55			$ 101
Actual %, year-on-year	13%			13%
Koselugo | Emerging Markets
Product sales
Product Sales	$ 24			$ 83
Actual %, year-on-year	73%
CER %, year-on-year	80%
Koselugo | Europe
Product sales
Product Sales	$ 26			$ 45
Actual %, year-on-year				95%
CER %, year-on-year				92%
Koselugo | Established ROW
Product sales
Product Sales	$ 9			$ 18
Actual %, year-on-year	63%
CER %, year-on-year	85%
Kanuma
Product sales
Product Sales	$ 47			$ 100
Actual %, year-on-year	3%			17%
CER %, year-on-year	8%			20%
Kanuma | US
Product sales
Product Sales	$ 25			$ 47
Actual %, year-on-year	21%			18%
Kanuma | Emerging Markets
Product sales
Product Sales	$ 5			$ 19
Actual %, year-on-year	(54.00%)			7%
CER %, year-on-year	(49.00%)			20%
Kanuma | Europe
Product sales
Product Sales	$ 15			$ 30
Actual %, year-on-year	28%			24%
CER %, year-on-year	33%			25%
Kanuma | Established ROW
Product sales
Product Sales	$ 2			$ 4
Actual %, year-on-year	11%			11%
CER %, year-on-year	41%			20%
Andexxa
Product sales
Product Sales	$ 59			$ 105
Actual %, year-on-year	29%			18%
CER %, year-on-year	35%			21%
Andexxa | US
Product sales
Product Sales	$ 22			$ 42
Actual %, year-on-year	34%			14%
Andexxa | Emerging Markets
Product sales
Product Sales	$ 1			$ 2
Andexxa | Europe
Product sales
Product Sales	$ 22			$ 40
Actual %, year-on-year	51%			38%
CER %, year-on-year	51%			36%
Andexxa | Established ROW
Product sales
Product Sales	$ 14			$ 21
Actual %, year-on-year	(6.00%)			(9.00%)
CER %, year-on-year	8%			4%
Total Other medicines
Product sales
Product Sales	$ 267			$ 560
Actual %, year-on-year	(11.00%)			(9.00%)
CER %, year-on-year	(5.00%)			(2.00%)
Total Other medicines | US
Product sales
Product Sales	$ 28			$ 52
Actual %, year-on-year	(13.00%)			(24.00%)
Total Other medicines | Emerging Markets
Product sales
Product Sales	$ 179			$ 385
Actual %, year-on-year	(3.00%)			(1.00%)
CER %, year-on-year	5%			8%
Total Other medicines | Europe
Product sales
Product Sales	$ 24			$ 53
Actual %, year-on-year	(7.00%)			10%
CER %, year-on-year	(7.00%)			10%
Total Other medicines | Established ROW
Product sales
Product Sales	$ 36			$ 70
Actual %, year-on-year	(38.00%)			(35.00%)
CER %, year-on-year	(32.00%)			(29.00%)
Nexium
Product sales
Product Sales	$ 219			$ 459
Actual %, year-on-year	(12.00%)			(7.00%)
CER %, year-on-year	(5.00%)			1%
Nexium | US
Product sales
Product Sales	$ 25			$ 47
Actual %, year-on-year	(17.00%)			(22.00%)
Nexium | Emerging Markets
Product sales
Product Sales	$ 146			$ 318
Actual %, year-on-year	(2.00%)			4%
CER %, year-on-year	7%			15%
Nexium | Europe
Product sales
Product Sales	$ 13			$ 26
Actual %, year-on-year	(5.00%)			3%
CER %, year-on-year	(5.00%)			2%
Nexium | Established ROW
Product sales
Product Sales	$ 35			$ 68
Actual %, year-on-year	(37.00%)			(34.00%)
CER %, year-on-year	(32.00%)			(28.00%)
Other, Others
Product sales
Product Sales	$ 48			$ 101
Actual %, year-on-year	(9.00%)			(17.00%)
CER %, year-on-year	(6.00%)			(14.00%)
Other, Others | US
Product sales
Product Sales	$ 3			$ 5
Actual %, year-on-year	39%			(40.00%)
Other, Others | Emerging Markets
Product sales
Product Sales	$ 33			$ 67
Actual %, year-on-year	(8.00%)			(22.00%)
CER %, year-on-year	(4.00%)			(18.00%)
Other, Others | Europe
Product sales
Product Sales	$ 11			$ 27
Actual %, year-on-year	(9.00%)			18%
CER %, year-on-year	(9.00%)			19%
Other, Others | Established ROW
Product sales
Product Sales	$ 1			$ 2
Actual %, year-on-year	(54.00%)			(53.00%)
CER %, year-on-year	(49.00%)			(49.00%)
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP.

Alliance Revenue (Details)

Alliance Revenue (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2024	[1]	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of products and services [line items]
Alliance revenue	$ 482		$ 341	$ 939	$ 627
Enhertu
Disclosure of products and services [line items]
Alliance revenue				683	475
Tezspire
Disclosure of products and services [line items]
Alliance revenue				180	105
Beyfortus
Disclosure of products and services [line items]
Alliance revenue				26
Other Alliance Revenue
Disclosure of products and services [line items]
Alliance revenue				$ 50	$ 47
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP.

Collaboration Revenue (Details)

Collaboration Revenue (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2024	[1]	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues
Total collaboration revenue	$ 4		$ 193	$ 49	$ 220
Farxiga: sales milestones
Revenues
Total collaboration revenue				$ 49	25
COVID-19 mAbs: licence fees
Revenues
Total collaboration revenue					180
Other Collaboration Revenue
Revenues
Total collaboration revenue					$ 15
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP.

Other operating income and ex_3

Other operating income and expense (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2024	[1]	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating profit, other operating income and expense
Total other operating income and expense	$ 60		$ 784	$ 127	$ 1,163
Brazikumab licence termination funding
Operating profit, other operating income and expense
Total other operating income and expense					75
Divestment of US rights to Pulmicort Flexhaler
Operating profit, other operating income and expense
Total other operating income and expense					241
Update to the contractual relationships for Beyfortus (nirsevimab)
Operating profit, other operating income and expense
Total other operating income and expense					712
Other
Operating profit, other operating income and expense
Total other operating income and expense				$ 127	$ 135
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP.